
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>bioa-ex101_204.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bioa-ex101_204.htm
</title>
</head>
<!-- NG Converter v4.0.3.7 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M1"></a><a name="_DV_M1"></a>Execution Version</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECOND AMENDED AND RESTATED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_DV_M3"></a>JOINT VENTURE AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M4"></a>by and among</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_DV_M5"></a>BIOAMBER INC.,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M6"></a>BIOAMBER INTERNATIONAL S.&#224;.r.l.,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_DV_M7"></a>MITSUI &amp; CO., LTD.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M8"></a>and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><a name="_DV_M9"></a>BIOAMBER SARNIA INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M10"></a>Dated February 15, 2016 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><a name="_DV_M11"></a><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-family:Times New Roman;"></font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">DEFINITIONS AND INTERPRETATION</font><font style="font-size:12pt;font-family:Times New Roman;"></font><font style="font-size:12pt;font-family:Times New Roman;">1</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Definitions1</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Interpretation.11</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">THE COMPANY12</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Formation12</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Name12</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Principal Place of Business12</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Subsidiaries; Shareholders12</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Foreign Qualification13</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Term13</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">BUSINESS OF THE COMPANY13</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Business13</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Initial Plant Commission and Capacity13</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">ADDITIONAL PLANT13</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Additional Plant13</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Construction of Additional Plant13</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">PBS Technology13</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Non-Binding Provisions14</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">FINANCING OF THE COMPANY14</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Financing Commitments of the Shareholders.14</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Additional Financial Contributions.16</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Share Valuation16</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Guarantees17</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Comerica Loan Agreement.18</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Convertible Loan19</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">BDC Credit Facility.21</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">NON-FINANCIAL CONTRIBUTIONS22</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">BioAmber Non-Financial Contributions22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Mitsui Non-Financial Contributions22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Provision of Non-Financial Contributions22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">REDUCTION/TERMINATION OF CONTRIBUTIONS22</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">i</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:12pt;font-family:Times New Roman;"></font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Reduction/Termination of Contributions</font><font style="font-size:12pt;font-family:Times New Roman;"></font><font style="font-size:12pt;font-family:Times New Roman;">22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Termination of Secondments/Assignments22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Action by the Parties22</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">MANAGEMENT OF THE COMPANY23</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Shareholders.23</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Board.26</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Officers.29</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Plant Manager29</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Secondment29</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Commissioning &amp; Start-Up Team30</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">EPC Matters30</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.8</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Annual Budget30</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">OTHER OPERATIONAL MATTERS30</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Opportunity Assessments30</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Dividend/Distribution Policy31</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Books and Records; Financial Statements.31</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Information Rights.31</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Insurance32</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">ENCUMBRANCE OR TRANSFER OF SHARES32</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Proxies and Voting Trusts32</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Restrictions on Transfer.32</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">RIGHT OF FIRST OFFER; RIGHT OF FIRST REFUSAL; DRAG-ALONG; CO-SALE33</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Right of First Offer.33</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Right of First Refusal.34</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">BioAmber Drag-Along Right.35</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Mitsui Co-Sale Right.36</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Terms of Mitsui Share Transfer37</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">PUT/CALL OPTIONS37</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Put/Call Option37</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Mitsui Put Option During Construction of the Initial Plant37</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;"></font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Mitsui Put Option Resulting from the </font><font style="font-size:12pt;font-family:Times New Roman;">Occurrence of a Dissolution Event</font><font style="font-size:12pt;font-family:Times New Roman;"></font><font style="font-size:12pt;font-family:Times New Roman;">37</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Additional Mitsui Put Option38</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Exercise of Options; Closing38</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.6</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Loans; Guarantees38</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">CLOSING OF SHARE TRANSFERS38</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Time and Place38</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Closing Deliveries39</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">No Encumbrances; Transfer Taxes39</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Effect of Share Transfer39</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">PREEMPTIVE RIGHTS, OVERSUBSCRIPTION RIGHTS39</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Restrictions39</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Notice40</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Exercise of Rights40</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">NON-COMPETE40</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Non-Compete40</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Exercise of Drag-Along Right40</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">CERTAIN ADDITIONAL AGREEMENTS AND UNDERTAKINGS40</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">General Shareholder Obligations40</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Initial Plant41</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Certain Operational Matters.41</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Additional Agreements42</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.5</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Supply Contracts43</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">REPRESENTATIONS AND WARRANTIES43</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Survival of Representations and Warranties contained in the Original JVA43</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">BioAmber Parties&#8217; Representations and Warranties43</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Mitsui&#8217;s Representations and Warranties44</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Survival of Representations and Warranties45</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">DEFAULT46</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Events of Default.46</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Option to Buy/Sell Upon an Event of Default.47</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">DISSOLUTION48</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;"></font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;">Dissolution Events</font><font style="font-size:12pt;font-family:Times New Roman;"></font><font style="font-size:12pt;font-family:Times New Roman;">48</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Distribution of Remaining Assets48</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Right to Prevent Dissolution48</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">TERMINATION48</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Termination of the Agreement48</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Consequences of Termination48</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">INDEMNIFICATION49</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">General Indemnification49</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">IP Indemnification49</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">No Consequential Damages49</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">DISPUTE RESOLUTION49</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Escalation Procedure49</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Arbitration.49</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:93.38%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">MISCELLANEOUS51</font></p></td>
<td valign="top" style="width:6.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">No Partnership51</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.2</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Discrepancies51</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.3</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Notices.51</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.4</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Expenses52</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.5</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Entire Agreement52</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.6</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Counterparts52</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.7</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Governing Law52</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.8</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Severability53</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.9</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Survival of Rights, Duties and Obligations53</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.10</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Specific Performance53</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.11</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Assignment53</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.12</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Amendment; Waiver53</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.13</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Limitation on Rights of Third Parties53</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.14</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Confidentiality.54</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.15</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Advertising; Publicity55</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.16</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Subsequent Shareholders55</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.17</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-size:12pt;font-family:Times New Roman;">Unanimous Shareholder Agreement55</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">SECOND AMENDED AND RESTATED JOINT VENTURE AGREEMENT</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M12"></a>THIS SECOND AMENDED AND RESTATED JOINT VENTURE AGREEMENT (this &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) is made and entered into as of the 15<sup style="font-size:85%; vertical-align:top">th</sup> day of February, 2016, by and among BioAmber Inc., a corporation organized under the laws of Delaware (&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber</font>&#8221;), BioAmber International S.&#224;.r.l., a limited liability company<font style="font-weight:bold;"> </font>organized under the laws of Luxembourg and a direct wholly owned subsidiary of BioAmber (&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Lux</font>&#8221;, and together with BioAmber, the &#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Parties</font>&#8221;), Mitsui &amp; Co., Ltd., a corporation organized under the laws of Japan (&#8220;<font style="font-weight:bold;font-style:italic;">Mitsui</font>&#8221;), and BioAmber Sarnia Inc., a corporation organized under the laws of Canada (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M13"></a>RECITALS</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M14"></a>A.&nbsp;&nbsp;Pursuant to certain Share Subscription Agreements, dated as of November 2, 2011, as amended by Share Subscription Amending Agreements dated as of January 24, 2014 (together, as so amended, the &#8220;<font style="font-weight:bold;font-style:italic;">Subscription Agreements</font>&#8221;), entered into by each of BioAmber Lux and Mitsui with the Company, BioAmber Lux and Mitsui originally acquired Shares representing seventy percent (70%) and thirty percent (30%), respectively, of the total outstanding Shares, on a fully diluted basis.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M15"></a><a name="_DV_M16"></a><a name="_DV_M16"></a>B.&nbsp;&nbsp;In connection with the acquisition by Mitsui and BioAmber Lux of their Shares pursuant to the respective Subscription Agreements, the parties entered into a Joint Venture Agreement, dated as of November 2, 2011 (the &#8220;<font style="font-weight:bold;font-style:italic;">Original JVA</font>&#8221;), which the parties subsequently amended and restated as of January 24, 2014 (as so amended and restated, the &#8220;<font style="font-weight:bold;font-style:italic;">First Amended and Restated JVA</font>&#8221;), to provide for certain matters relating to, among other things, the management and operation of the Company.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:0pt;">&nbsp;&nbsp;In exchange for the First Additional Mitsui Capital Contribution (as defined below), the Company has issued to Mitsu</font>i additional Shares.&nbsp;&nbsp;Accordingly, as of the date hereof, the Pro Rata Shares (as defined below) of BioAmber Lux and Mitsui are sixty-four and one-tenth percent&nbsp;&nbsp;(64.1%) and thirty-five and nine-tenths percent (35.9%), respectively.<sup style="font-size:85%; vertical-align:top"> </sup></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.&nbsp;&nbsp;The parties desire to amend certain aspects of the First Amended and Restated JVA, and restate the First Amended and Restated JVA in its entirety to reflect such amendments, effective from the date of and as set forth in this Agreement.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;"><a name="_DV_M17"></a>NOW, THEREFORE<font style="font-variant: normal;">, the parties agree as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M18"></a><a name="_DV_M19"></a><a name="_Ref301953163"></a><a name="_Toc444101275"></a>DEFINITIONS AND INTERPRETATION</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M20"></a><a name="_Toc444101276"></a><font style="text-decoration:underline;">Definitions</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The following capitalized terms used herein shall have the following meanings unless the context otherwise requires:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M21"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Absent Shareholder</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 8.1.7</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M22"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Additional Contribution</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.2.1</font>.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M23"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Additional Plant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;">Section 4.1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M24"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Affiliate</font>&#8221; means, with respect to a specified Person, any other Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by, or is under common Control with, such specified Person.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M25"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Agent</font>&#8221; means Comerica Bank, as administration agent with respect to the Comerica Loan Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221; has the meaning set forth in the preamble hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M26"></a>&#8220;<font style="font-weight:bold;font-style:italic;">AIP Loan Agreement</font>&#8221; means that certain repayable contribution agreement for the Agriinnovation Program: Enabling Commercialization and Adoption Stream, dated as of March 10, 2014, among Her Majesty the Queen in Right of Canada, as represented by the Minister of Agriculture and Agri-Food, BioAmber and the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Ancillary Agreements</font>&#8221;<font style="font-weight:bold;font-style:italic;"> </font>means (a) the Amended and Restated Technology License Agreement, (b) the Trademark License Agreement, (c) the BioAmber Services Agreement, (d) the Mitsui Services Agreement, (e) the Assignment Agreement, (f) the Indemnification Agreement, (g)&#160;the Financial Support Implementing Agreement, (h)&#160;the Reimbursement Agreements and (i)&#160;the Master Marketing and Sales Agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M27"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Applicable Law</font>&#8221; means all applicable provisions of all (a) constitutions, treaties, statutes, laws (including common law), rules, regulations, ordinances or codes; and (b) orders, decisions, judgments, awards or decrees, in each case of any Governmental Authority of the United States of America, Canada, Japan or other applicable jurisdictions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M28"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Appraiser</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.3.2(a)</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M29"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Arbitration Party</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 22.2.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M30"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Assignment Agreement</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 16.4.4</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M31"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BDC</font>&#8221; means the Business Development Bank of Canada.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">BDC Credit Facility</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;5.7.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">BDC Definitive Agreements</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;5.7.2</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">BDC Letter of Intent</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;5.7.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">BDO</font>&#8221; means 1,4 Butanediol and Tetrahydrofuran (THF) produced from BSA using the DuPont Technology.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M32"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber</font>&#8221; has the meaning set forth in the preamble hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">2</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M33"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">BioAmber IP</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means all Intellectual Property Rights owned, co- or jointly owned, or held by BioAmber or its Affiliates that are necessary, useful or otherwise related to the operation of the Business.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M34"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber IP Agreements</font>&#8221; means any and all Contracts concerning Intellectual Property Rights that are necessary, useful or otherwise related to the operation of the Business to which BioAmber or any BioAmber Affiliate is a party or beneficiary, or by which BioAmber or any BioAmber Affiliate, or any of its properties or assets, may be bound, including:&nbsp;&nbsp;(a) licenses of Intellectual Property Rights by BioAmber or any BioAmber Affiliate to any third party, (b)&#160;licenses of Intellectual Property Rights by any third party to BioAmber or any BioAmber Affiliate, (c) Contracts between BioAmber or any BioAmber Affiliate and any third party relating to the transfer, development, maintenance or use of Intellectual Property Rights, (d) covenants not to sue under or releases from any claim of damages for infringement, unauthorized use or disclosure, or misappropriation of any third party&#8217;s Intellectual Property Rights and (e) Consents, settlements, decrees, orders, injunctions, judgments or rulings governing the use, validity or enforceability of Intellectual Property Rights.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M35"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Lux</font>&#8221; has the meaning set forth in the preamble hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M36"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Parties</font>&#8221; has the meaning set forth in the preamble hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M37"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Right to Approve</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 8.1.2</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M38"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Services Agreement</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 16.4.2</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M39"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Technology</font>&#8221; means the BioAmber IP and the Licensed IP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M40"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Triggering Event</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.3.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M41"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Triggering Event Notice</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.4.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M42"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Board</font>&#8221; means the board of directors of the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M43"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Books and Records</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 9.3.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M44"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Book Value</font>&#8221; means, with respect to a Share, the aggregate book value of the Company&#8217;s net assets (calculated as the Company&#8217;s total assets minus its total liabilities) based on the balance sheet of the Company for the last Financial Year, or latest complete quarter or month, whichever is most recent, divided by the number of outstanding Shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M45"></a>&#8220;<font style="font-weight:bold;font-style:italic;">BSA</font>&#8221; means bio-based succinic acid.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M46"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Business</font>&#8221;<font style="font-weight:bold;font-style:italic;"> </font>has the meaning set forth in <font style="text-decoration:underline;">Section 3.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M47"></a>&#8220;<font style="font-weight:bold;font-style:italic;">CCO</font>&#8221; means the Chief Commercial Officer of the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">3</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Change</font><font style="font-weight:bold;font-style:italic;"> of Control</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; with respect to a Person means the occurrence of any of the following events:&nbsp;&nbsp;(a) the acquisition by any other Person or group of Persons, through any transaction or series of related transactions, of Control of such Person; (b) such Person c</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onsolidates with, or merges with or into, another Entity, whether or not such Person is the surviving Entity of such transaction, unless immediately after such consolidation or merger the Person or group of Persons who Controlled such Person immediately pr</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ior to the transaction Control such surviving Entity; or (c) a sale or other transfer of all or a substantially all of the assets or business of such Person.&nbsp;&nbsp;In addition, a &#8220;Change of Control&#8221; with respect to BioAmber Lux (or any Permitted Transferee ther</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eof) shall be deemed to occur if BioAmber sells or otherwise transfers all or substantially all of its BSA-related assets or business (including the BioAmber Technology).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M48"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Charter Documents</font>&#8221; of any Person means such Person&#8217;s articles of incorporation, certificate of formation, memorandum or articles of association, by-laws or equivalent governing or organizational documents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M49"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Comerica Loan Agreement</font>&#8221; means that certain Loan Agreement, dated as of June 20, 2014, as amended by a waiver and first amending agreement dated as of May 12, 2015 (and as it may be further amended from time to time), among the Company, the Lenders party thereto and the Agent, governing the terms of a credit facility to the Company in the aggregate principal amount of up to $20,000,000.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221; has the meaning set forth in the preamble hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M50"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Company Bank Account</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Schedule 1.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Company Valuation</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;5.3.2</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M51"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Confidential Information</font>&#8221; means all Trade Secrets and other confidential and/or proprietary information of a Person, including business, technical, or financial information relating to the matters contemplated hereby, the terms or existence of this Agreement or other matters relating to the operation of the Business contemplated hereby.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M52"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Consent</font>&#8221; means any approval, consent, ratification, permission, waiver or authorization (including by or from any Governmental Authority)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M53"></a><a name="_DV_M54"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Contract</font>&#8221; means any agreement, contract, consensual obligation, promise, understanding, arrangement, commitment or undertaking of any nature (whether written or oral and whether express or implied), whether or not legally binding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M55"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Contribution Notice</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.2.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M56"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Control</font>&#8221; of a Person (and, with correlative meaning, &#8220;<font style="font-weight:bold;font-style:italic;">Controls</font>&#8221; and &#8220;<font style="font-weight:bold;font-style:italic;">Controlled</font>&#8221;) means (i) the ownership of a majority of the voting securities of such Person or (ii) the possession, direct or indirect, of the power to direct or cause the direction of the management and </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">4</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">policies of such Person, whether th</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rough the ownership of Equity Securities, by Contract or otherwise.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M57"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Convertible Loan</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;5.6.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Copyrights</font>&#8221; means all copyrights and copyrightable works, and applications for registration thereof, including all rights of authorship, publication, reproduction, distribution, performance and transformation and moral rights, together with all other interests accruing by reason of international copyright conventions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M58"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Co-Sale Right</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.4.2</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M59"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Defaulting Shareholder</font>&#8221; means a Shareholder in respect of whom an Event of Default has occurred and is continuing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M60"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Default Option Exercise Notice</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 18.2.5</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M61"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Defending Party</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 22.2.5</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M62"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Director</font>&#8221; means a member of the Board.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M63"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Disclosing Party</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 23.14.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M64"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Dispute</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 22.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M65"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Dissolution Event</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 19.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M66"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Dissolution Notice</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 19.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M67"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Dollars</font>&#8221; or &#8220;<font style="font-weight:bold;font-style:italic;">$</font>&#8221; refers to lawful currency of Canada.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M68"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Dow Chemical</font>&#8221; means The Dow Chemical Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M69"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Drag-Along Expiration Date</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.3.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M70"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Drag-Along Right</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.3.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M71"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Dupont</font>&#8221; means E. I. du Pont de Nemours.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M72"></a>&#8220;<font style="font-weight:bold;font-style:italic;">DuPont Technology</font>&#8221; means all Intellectual Property Rights licensed or sublicensed by Dupont to BioAmber or a BioAmber Affiliate that are necessary or useful to or otherwise used in connection with the production of BDO, including all Patents and other Intellectual Property Rights licensed to BioAmber S.A.S. under the License Agreement, dated as of June 28, 2010, between DuPont and BioAmber S.A.S.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M73"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Encumber</font>&#8221; and &#8220;<font style="font-weight:bold;font-style:italic;">Encumbrance</font>&#8221; have the respective meanings set forth in <font style="text-decoration:underline;">Section 10.2.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">5</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M74"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Entity</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any corporation (including any non-profit corporation), general partnership, limited</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> partnership, limited liability partnership, joint venture, estate, trust or company (including any limited liability company or joint stock company).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M75"></a>&#8220;<font style="font-weight:bold;font-style:italic;">EPC Contract</font>&#8221; means, collectively, one or more engineering, procurement and/or construction contracts to be entered into between the Company and one or more EPC Firms in respect of Phase I of the Initial Plant consisting of the construction of the initial phase of the Initial Plant having an initial annual capacity of 30,000 MT of BSA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M76"></a>&#8220;<font style="font-weight:bold;font-style:italic;">EPC Firm</font>&#8221; or &#8220;<font style="font-weight:bold;font-style:italic;">EPC Firms</font>&#8221;means, collectively, the engineering, procurement and/or construction firm(s) retained by the Company for the construction of the Initial Plant pursuant to the EPC Contract.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M77"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Equity Securities</font>&#8221; means, with respect to any Person, such Person&#8217;s capital stock, issued share capital, membership interests, partnership interests, registered capital, joint venture or other ownership interests or any options, warrants or other securities that are directly or indirectly convertible into, or exercisable or exchangeable for, such capital stock, issued share capital, membership interests, partnership interests, registered capital, joint venture or other ownership interests (whether or not such derivative securities are issued by such Person).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M78"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Event of Default</font>&#8221;<font style="font-weight:bold;font-style:italic;"> </font>has the meaning set forth in <font style="text-decoration:underline;">Section 18.1.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M79"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Fair Market Value</font>&#8221; means fair market value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M80"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Financial Statements</font>&#8221; means the financial statements of the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M81"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Financial Support Implementing Agreement</font>&#8221; means that certain Financial Support Implementing Agreement, dated as of May 25, 2015, among the BioAmber Parties and Mitsui.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Financial Year</font>&#8221; means the financial or fiscal year of the Company, which shall end on December 31 of each year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M82"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Financing Share Price</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.3.2</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M83"></a>&#8220;<font style="font-weight:bold;font-style:italic;">First Additional Mitsui Capital Contribution</font>&#8221; means the amount of $12,500,000 provided by Mitsui to the Company as a capital contribution as of February 12, 2016, in accordance with the Term Sheet.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">First Amended and Restated JVA</font>&#8221; has the meaning set forth in the recitals hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">First Refusal Notice</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;11.2.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Governmental Approval</font>&#8221; means any:&nbsp;&nbsp;permit, license, certificate, concession, approval, consent, ratification, permission, clearance, confirmation, exemption, waiver, franchise, certification, designation, rating, registration, variance, qualification, accreditation or </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">6</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorization issued, granted, given or otherwise made available</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by any Governmental Authority.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M84"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Governmental Authority</font>&#8221; means (a) any government or political subdivision thereof (including any state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature); (b) any department, agency or instrumentality of any government or political subdivision thereof; (c) any court or arbitral tribunal; and (d) the governing body of any securities exchange, in each case having competent jurisdiction.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M85"></a><a name="_DV_M86"></a><a name="_DV_M87"></a>&#8220;<font style="font-weight:bold;font-style:italic;">ICC</font>&#8221; means the International Chamber of Commerce.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M88"></a>&#8220;<font style="font-weight:bold;font-style:italic;">ICC Rules</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 22.2.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M89"></a>&#8220;<font style="font-weight:bold;font-style:italic;">IFRS</font>&#8221; means the international accounting standards or the international financial reporting standards prescribed by the International Accounting Standards Board and its successors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M90"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Indemnification Agreement</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 8.2.14</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M91"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Initial Plant</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 3.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M92"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Initial Plant Site</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 17.1.16</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M93"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Intellectual Property Rights</font>&#8221; means all right, title, and interest arising from or in respect of any of the following, whether protected, created or arising under the laws of the United States or any other jurisdiction: (a) all Patents; (b) all Trademarks; (c) all Copyrights; (d) Trade Secrets or Know-how; and (e) all rights, benefits, privileges, causes of action, and remedies relating to any of the foregoing, whether before or hereafter accrued, including the exclusive rights to apply for and maintain all registrations, renewals, and extensions, to sue for all past, present, and future infringements, unauthorized uses or disclosures, or misappropriations of any rights relating thereto, and to settle and retain proceeds from any such actions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M94"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Issuance Notice Period</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 14.3</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M95"></a>&#8220;<font style="font-weight:bold;font-style:italic;">IPO</font>&#8221; means an initial public offering of Equity Securities pursuant to a prospectus, an effective registration statement, a listing agreement or otherwise in any jurisdiction.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M96"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Joinder Agreement</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 23.16</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M97"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Know-how</font>&#8221; means all title, right and interest in all Trade Secrets, ideas, methods, concepts, proprietary techniques, processes, formulae, specifications, inventions and discoveries (whether patentable or unpatentable and whether or not reduced to practice), business and other methodologies, scientific, technical, research, development, engineering and business information, and other know-how, including all Trade Secret rights arising under any law, including common law, state law, federal law or laws of foreign countries, other than Copyrights, Patents and Trademarks.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">7</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M98"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Lenders</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any third-party lenders of the Company.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M99"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Licensed IP</font>&#8221; means any and all Intellectual Property Rights that BioAmber or its Affiliates are licensed or otherwise permitted by other Persons to use under the BioAmber IP Agreements that are necessary, useful or otherwise related to the operation of the Business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M100"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Loss</font>&#8221; means any loss, damage, injury, decline in value, liability, claim, demand, settlement, judgment, award, fine, penalty, tax, fee (including any attorney&#8217;s, accountant&#8217;s, expert&#8217;s or other advisor&#8217;s fees, costs and expenses), charge, cost (including any cost of investigation) or expense of any nature, whether or not involving a third-party claim.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M101"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Marketing Policy</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Schedule&#160;8.1.3(m)</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Master Marketing and Sales Agreements</font>&#8221; means (a)&#160;that certain Master Marketing and Sales Agreement, dated as of February 8, 2016, between BioAmber and the Company, and (b)&#160;that certain Master Marketing and Sales Agreement, dated as of February 8, 2016, between Mitsui and the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Minimum Volume</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;9.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Mitsui</font>&#8221; has the meaning set forth in the preamble hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M102"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Mitsui Maximum Commitment</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.1.5</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M103"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Mitsui Services Agreement</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 16.4.3</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M104"></a>&#8220;<font style="font-weight:bold;font-style:italic;">NatureWorks</font>&#8221; means NatureWorks LLC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M105"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Offered Shares</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.1.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M106"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Offering Shareholder</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.1.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M107"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Offering Shareholder Terms</font>&#8221; has the meaning specified in <font style="text-decoration:underline;">Section 11.1.4</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M108"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Offer Notice</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.1.2</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M109"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Operational Date</font>&#8221; means the date on which (i) the physical facilities of the Initial Plant have been constructed, installed, commissioned and become operational and (ii) the Initial Plant has had a period of ten&#160;(10) days of continuous operation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M110"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Opportunity Assessment</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;9.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Original JVA</font>&#8221; has the meaning set forth in the recitals hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Oversubscription Rights</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 14.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">8</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M111"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">party</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any signatory to this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement and any Person that subsequently becomes a party to this Agreement as provided herein.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M112"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Patents</font>&#8221; means all patent rights, title and interests in and to all letters patent and rights accorded under patent law systems, utility models, and applications therefor, including continuations, divisionals, continuations-in-part, reissues, reexaminations, substitutions, renewals, and extensions thereof, foreign counterparts thereto, and patents issuing thereon.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M113"></a>&#8220;<font style="font-weight:bold;font-style:italic;">PBS</font>&#8221; means a polymer comprised primarily of residues of diacids and diols, wherein the diacid component comprises at least 65% by mole of BSA and the diol component comprises at least 65% by mole of BDO.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M114"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Permitted Issuance</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 14.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M115"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Permitted Transferee</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 10.2.3</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M116"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Person</font>&#8221; means any individual, Entity or Governmental Authority.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M117"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Petitioning Party</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 22.2.5</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M118"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Plant Manager</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 8.1.2(c)</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M119"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Preemptive Rights</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 14.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M120"></a>&#8220;<font style="font-weight:bold;font-style:italic;">President</font>&#8221; means the President of the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Proceeding</font>&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination or investigation that is, has been or may in the future be commenced, brought, conducted or heard at law or in equity or before any Governmental Authority or any arbitrator or arbitration panel.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M121"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Proposed Issuance</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 14.2</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M122"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Proposed Recipient</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 14.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M123"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Pro Rata Share</font>&#8221; means, with respect to a Shareholder, the proportion that the number of Shares held by such Shareholder (together with any Permitted Transferee thereof) bears to the aggregate number of Shares held by all Shareholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M124"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Provisional Remedy</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 22.2.6</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M125"></a>&#8220;<font style="font-weight:bold;font-style:italic;">PTT-MCC Biochem</font>&#8221; means PTT MCC Biochem Ltd.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M126"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Receiving Party</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 23.14.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">9</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M127"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Reimbursement Agreements</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means (a)&#160;that certain Reimbursement Agreement, dated as of July 31, 2015, between the Company and Mitsui, in </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relation to Mitsui&#8217;s guaranty with respect to the Comerica Loan Agreement, and (b)&#160;that certain Reimbursement Agreement, dated as of July 31, 2015, between the Company and Mitsui, in relation to Mitsui&#8217;s guaranty with respect to the SJIF Loan Agreement.&#160;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Registered IP Assets</font>&#8221; means Patents, registered Trademarks, and registered Copyrights, including any pending applications for any of the foregoing owned by BioAmber or any of its Affiliates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M128"></a>&#8220;<font style="font-weight:bold;font-style:italic;">ROFO Exercise Notice</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.1.3</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M129"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Second Additional Mitsui Capital Contribution</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;5.1.3(a)</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Secretary</font>&#8221; means the secretary of the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M130"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Shareholder</font>&#8221; means (i) BioAmber Lux, (ii) Mitsui or (iii) any other Person who becomes a holder of Shares in accordance with the terms of this Agreement and executes a Joinder Agreement, in each case for so long as such Person remains a holder of any Shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M131"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Shares</font>&#8221; means all ordinary shares in the share capital of the Company that may be authorized and issued from time to time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M132"></a>&#8220;<font style="font-weight:bold;font-style:italic;">SJIF Loan Agreement</font>&#8221; means that certain Loan Agreement, dated as of September 30, 2011 (as amended from time to time), between Her Majesty The Queen In Right of the Province of Ontario, as represented by the Minister of Economic Development and Innovation (formerly known as the Minister of Economic Development and Trade), and the Company, governing the terms of a credit facility to the Company in the aggregate principal amount of up to $15,000,000.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Subscription Agreements</font>&#8221; has the meaning set forth in the recitals hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M133"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Supply Contracts</font>&#8221; means the Contracts set forth in <font style="text-decoration:underline;">Schedule 16.5</font>, as such Schedule may be amended from time to time as provided herein.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M134"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Technology License Agreement</font>&#8221; means that certain Amended and Restated Process and Technology License Agreement, dated as of January 24, 2014, as amended as of the date hereof (including pursuant to the Third Amendment to Technology License Agreement), among BioAmber, BioAmber Lux, as licensor, and the Company, as licensee, in respect of the production of BSA and BDO.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M135"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Term Sheet</font>&#8221; means that certain term sheet among the parties hereto, dated as of February 8, 2016, relating to the amendments to the First Amended and Restated JVA and the Technology License Agreement that are further implemented hereby and by the Third Amendment to Technology License Agreement, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">10</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Third Amendment to Technology License Agreement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means that certain third am</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">endment to the Technology License Agreement, entered into by BioAmber, BioAmber Lux and the Company concurrently with the execution of this Agreement, providing for an increase in the royalty rate payable by the Company to BioAmber Lux prior to the GTR Com</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pletion Date (as such term is defined in the Technology License Agreement) from *** of Product (as such term is defined in the Technology License Agreement) sold by the Company to third parties to *** for such sales&#160;(with the royalty rate applicable to sal</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es of Product by the Company following the GTR Completion Date (or ***) being unchanged).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Third Party Acquirer</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.3.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M136"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Trademark License Agreement</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 16.4.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M137"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Trademarks</font>&#8221; means all trademarks, service marks, trade names, service names, brand names, trade dress, together with the goodwill associated with any of the foregoing, and all applications, ITU Applications, registrations and renewals thereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M138"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Trade Secrets</font>&#8221; means any trade secrets or similar forms of protection for confidential information, including invention disclosures, formulae, recipes, specifications (including information regarding materials, ingredients, tools, apparatus, sources, vendors), procedures, processes, methods, techniques, ideas, creations, inventions and discoveries (whether patentable or unpatentable and whether or not reduced to practice), improvements, know-how, research and development, technical data, designs, models, algorithms, subroutines and similar confidential information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M139"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Transfer</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 10.2.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M140"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Transfer Negotiation Period</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.1.3</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M141"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Transferring BioAmber Party</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;11.2.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Transferring Shareholder</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.1.1</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M142"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Transfer Terms</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 11.1.3</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M143"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Tribunal</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 22.2.3</font>.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M144"></a>&#8220;<font style="font-weight:bold;font-style:italic;">Trigger Event</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section&#160;5.6.2</font>.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Valuation Deadline</font>&#8221; has the meaning set forth in <font style="text-decoration:underline;">Section 5.3.2</font>.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Vinmar</font>&#8221; means Vinmar International, Ltd. </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Vinmar TOP</font>&#8221; means that certain Master Product Offtake Agreement, dated as of July 3, 2014, among Vinmar, BioAmber and the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">11</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M145"></a><a name="_Toc444101277"></a><a name="_DV_M147"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">1.2</font><font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Interpretation</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M147"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M148"></a><a name="_DV_M149"></a><a name="_DV_M150"></a><a name="_DV_M151"></a>1.2.1<font style="margin-left:144pt;"></font><a name="_DV_M148"></a>The terms &#8220;herein,&#8221; &#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;hereinafter&#8221; and similar terms, as used in this Agreement, in each case shall refer to this Agreement as a whole and not to any particular section, <a name="_DV_M149"></a><a name="_DV_M150"></a>paragraph, sentence or other subdivision of this Agreement.&nbsp;&nbsp;Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used, they shall be deemed to be followed by the words &#8220;without limitation&#8221; or &#8220;but not limited to&#8221; or words of like import.&nbsp;&nbsp;The term <a name="_DV_M151"></a>&#8220;or,&#8221; as used herein, is not exclusive.&nbsp;&nbsp;Words used herein, regardless of the number and gender specifically used, shall be deemed and construed to include any other number, singular or plural, and any other gender, masculine, feminine or neuter, as the context indicates is appropriate.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M152"></a>1.2.2<font style="margin-left:144pt;"></font>Any reference to a statute or statutory provision shall be construed as a reference to the same as it may have been, or may from time to time be, amended, modified or re-enacted and to any applicable rules or regulations promulgated thereunder.&nbsp;&nbsp;Any reference to any agreement or document (including this Agreement) shall be construed as a reference to such agreement or document as amended, modified or supplemented and in effect from time to time and shall include a reference to any document which amends, modifies or supplements it, or is entered into, made or given pursuant to or in accordance with its terms.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M153"></a>1.2.3<font style="margin-left:144pt;"></font>Any reference to any Person in any capacity includes a reference to its permitted successors and assigns in such capacity and, in the case of any Governmental Authority, any Person succeeding to its functions and capacities.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M154"></a>1.2.4<font style="margin-left:144pt;"></font>Each party has participated in the drafting of this Agreement, and any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M155"></a>1.2.5<font style="margin-left:144pt;"></font>All references in this Agreement to &#8220;Section,&#8221; &#8220;Exhibit&#8221;, &#8220;Schedule&#8221; or &#8220;Annex&#8221; (or similar references) shall be deemed to be references to a section of, or exhibit, schedule or annex to, this Agreement, unless the context otherwise requires.&nbsp;&nbsp;Headings set forth in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M156"></a><a name="_DV_M157"></a><a name="_Toc444101278"></a>THE COMPANY</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M158"></a><a name="_Toc444101279"></a><font style="text-decoration:underline;">Formation</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M159"></a><a name="_DV_M159"></a>.&nbsp;&nbsp;The BioAmber Parties have formed the Company as a Canadian corporation in accordance with Applicable Law and subject to the terms and conditions set forth in this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M160"></a><a name="_Toc444101280"></a><font style="text-decoration:underline;">Name</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M161"></a><a name="_DV_M161"></a>.&nbsp;&nbsp;The name of the Company shall be BioAmber Sarnia Inc. unless changed by mutual agreement of the Shareholders.&nbsp;&nbsp;All business of the Company shall be conducted in the name of the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M162"></a><a name="_Toc444101281"></a><font style="text-decoration:underline;">Principal Place of Business</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M163"></a><a name="_DV_M163"></a>.&nbsp;&nbsp;The Company&#8217;s principal place of business shall be 1086, Modeland Road, Building 1010, Room 251, Sarnia, Ontario, N7S 6L2, unless changed to a </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">12</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">different location by mutual agreement of the Shareholders (it being understood that the foregoing address may </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">change once the Initial Plant is built).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M164"></a><a name="_Toc444101282"></a><font style="text-decoration:underline;">Subsidiaries; Shareholders</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The Company shall have no subsidiaries except if and to the extent agreed by all of the Shareholders.&nbsp;&nbsp;The Company shall have no Shareholders (other than the then-current Shareholders) except as expressly permitted by this Agreement or as all of the Shareholders may otherwise agree.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M165"></a><a name="_Toc444101283"></a><font style="text-decoration:underline;">Foreign Qualification</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M166"></a><a name="_DV_M166"></a>.&nbsp;&nbsp;Prior to the Company conducting business in any jurisdiction in which it is required, as a result of such activities, to qualify to do business, the Company shall comply with all requirements necessary to qualify it to do business in such jurisdiction.&nbsp;&nbsp;Each Shareholder shall execute and deliver any certificates and other instruments that are necessary or appropriate for the Company to qualify and continue to do business as a foreign entity in such jurisdiction.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M167"></a><a name="_Toc444101284"></a><font style="text-decoration:underline;">Term</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M168"></a><a name="_DV_M168"></a>.&nbsp;&nbsp;The Company shall continue in existence from its date of formation until its dissolution in accordance with the provisions of this Agreement, its Charter Documents and Applicable Law.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M169"></a><a name="_Ref174530514"></a><a name="_Ref300769440"></a><a name="_Toc444101285"></a><font style="text-transform:none;">BUSINESS OF THE COMPANY</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M170"></a><a name="_Toc444101286"></a><a name="_Ref174504537"></a><a name="_Ref301948376"></a><font style="text-decoration:underline;">Business</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M171"></a>.&nbsp;&nbsp;The business of the Company (the &#8220;<font style="font-weight:bold;font-style:italic;">Business</font>&#8221;) shall be to finance, build and operate a plant in Sarnia, Ontario, Canada to produce and sell BSA and BDO using the BioAmber Technology, and having the capaci<a name="_DV_M171"></a>ty (including expanded capacity) contemplated by <font style="text-decoration:underline;">Section 3.2</font> (the &#8220;<font style="font-weight:bold;font-style:italic;">Initial Plant</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M172"></a><a name="_Toc444101287"></a><a name="_Ref301952789"></a><font style="text-decoration:underline;">Initial Plant Commission and Capacity</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The Initial Plant has achieved mechanical completion with an initial annual capacity of approximately 30,000 MT of BSA and is presently under ramp-up of production.&nbsp;&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M174"></a><a name="_DV_M175"></a><a name="_DV_M176"></a><a name="_Ref302050958"></a><a name="_Toc444101288"></a><font style="text-transform:none;">ADDITIONAL PLANT</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M177"></a><a name="_Ref174529288"></a><a name="_Toc444101289"></a><a name="_Ref301949180"></a><a name="_Ref302459262"></a><a name="_DV_M178"></a><font style="text-decoration:underline;"><a name="_DV_M178"></a>Additional Plant</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref301949262"></a><a name="_Ref301949721"></a><a name="_Ref301949709"></a><a name="_Ref301949262"></a><a name="_Ref301949721"></a>.&nbsp;&nbsp;In addition to the Initial Plant, the BioAmber Parties and Mitsui intend to build and operate an additional plant to produce and sell BSA and BDO using the BioAmber Technology, or some combination thereof as the applicable parties may agree, to be located either in Canada or in United States (the &#8220;<font style="font-weight:bold;font-style:italic;"><a name="_Ref301949709"></a>Additional Plant</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M179"></a><a name="_DV_M180"></a><a name="_DV_M182"></a><a name="_DV_M185"></a><a name="_Toc444101290"></a><a name="_Ref302459266"></a><font style="text-decoration:underline;">Construction of Additional Plant</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The BioAmber Parties and Mitsui shall discuss in good faith the construction and operation of the Additional Plant, according to terms and conditions between them similar to those applicable to the Initial Plant or as such parties may otherwise agree.&nbsp;&nbsp;The BioAmber Parties and Mitsui will consider the possibility of seeking the participation of a local equity partner that can provide access to feedstock, offer operational </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">13</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">capabilities or enter into a meaningful off-take agreement in respect of the output of the Additional Plant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M186"></a><a name="_Toc444101291"></a><a name="_Ref302459268"></a><font style="text-decoration:underline;">PBS Technology</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;If the BioAmber Parties and Mitsui agree to jointly develop the Additional Plant, BioAmber may seek to secure rights to PBS technology in order to carry out integrated manufacturing of PBS at the Additional Plant through:&nbsp;&nbsp;(i) a partnership with PTT-MCC Biochem; (ii) a license from PTT-MCC Biochem; (iii) a sub-license from a licensee of PTT-MCC Biochem, such as NatureWorks; or (iv) a partnership with, or license from, another PBS technology provider.&nbsp;&nbsp;The BioAmber Parties and Mitsui shall negotiate in good faith Mitsui&#8217;s eventual involvement in PBS manufacturing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M187"></a><a name="_Toc444101292"></a><font style="text-decoration:underline;">Non-Binding Provisions</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the provisions of each of <font style="text-decoration:underline;">Sections 4.1</font>, <font style="text-decoration:underline;">4.2</font> and <font style="text-decoration:underline;">4.3</font> are a statement of intent only and are not, and shall not be deemed to be, binding obligations of either of the BioAmber Parties or Mitsui.&nbsp;&nbsp;Without limiting the generality of the foregoing, as between such parties, none of the BioAmber Parties nor Mitsui shall have any obligation in respect of the construction of the Additional Plant, which construction is subject to, among other things, satisfactory market feasibility studies, agreement on capital budgets and obtaining necessary internal approvals, all at the sole discretion of each such party.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M188"></a><a name="_DV_M189"></a><a name="_DV_M190"></a><a name="_Toc444101293"></a><font style="text-transform:none;">FINANCING OF THE COMPANY</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M191"></a><a name="_Ref174509968"></a><a name="_Ref301963125"></a><a name="_Toc444101294"></a><a name="_Ref161740895"></a><a name="_DV_M192"></a><a name="_DV_M193"></a>5.1<font style="margin-left:72pt;"></font><font style="text-decoration:underline;"><a name="_DV_M192"></a>Financing Commitments of the Shareholders</font><a name="_DV_M193"></a>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M194"></a><a name="_Ref372547806"></a><a name="_Ref304890705"></a>5.1.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BioAmber Lux Capital Contributions</font>.&nbsp;&nbsp;Pursuant to its Subscription Agreement and its funding of further capital calls by the Company, BioAmber Lux has provided to the Company as of the date hereof capital contributions in the aggregate amount of $95,900,000.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M195"></a><a name="_Ref304890623"></a>5.1.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Mitsui Capital Contributions</font>.&nbsp;&nbsp;Pursuant to its Subscription Agreement and its funding of further capital calls by the Company, Mitsui has provided to the Company as of the date hereof capital contributions in the aggregate amount of $53,600,000 (including therein the First Additional Mitsui Capital Contribution).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M196"></a><a name="_Ref372274772"></a>5.1.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Additional Capital Contributions</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443294190"></a>(a)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Second Additional Mitsui Capital Contribution</font>.&nbsp;&nbsp;Provided that none of the events set forth in <font style="text-decoration:underline;">Section&#160;18.1.1(c)</font> has occurred with respect to BioAmber, Mitsui shall provide to the Company, (i) no later than February 26, 2016, an additional capital contribution in an aggregate amount equal to $7,500,000, and (ii) no later than March 11, 2016, an additional capital contribution in an aggregate amount equal to $5,000,000 (collectively, the &#8220;<font style="font-weight:bold;font-style:italic;">Second Additional Mitsui Capital Contribution</font>&#8221;), by wire transfer of immediately available funds to the Company Bank Account.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(b)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Use of Proceeds</font>.&nbsp;&nbsp;The proceeds of the First Additional Mitsui Capital Contribution and the Second Additional Mitsui Capital Contribution shall </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">14</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">be used t</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">o fund the cash requirements of the Company, including fulfilling its outstanding payment obligations to counterparties such as EPC Firms, suppliers and service providers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M197"></a><a name="_Ref301971620"></a><a name="_Ref307666851"></a><a name="_Ref443301068"></a><a name="_DV_M198"></a><a name="_DV_M206"></a><a name="_DV_C6"></a><a name="_DV_M199"></a><a name="_DV_C7"></a><a name="_DV_M200"></a><a name="_DV_M201"></a><a name="_DV_C10"></a><a name="_DV_M202"></a><a name="_DV_C12"></a><a name="_DV_M203"></a><a name="_DV_C13"></a><a name="_DV_M204"></a><a name="_DV_C14"></a><a name="_DV_M205"></a>5.1.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Loan Guarantees</font>.&nbsp;&nbsp;As of the date hereof, BioAmber Lux (or BioAmber, as the case may be) and Mitsui have provided guarantees in favor of Lenders in respect of loans provided by such Lenders to the Company, in the respective amounts set forth in <font style="text-decoration:underline;">Schedule&#160;5.1.4</font>, and, for the avoidance of doubt, neither any of the BioAmber Parties nor Mitsui is presently required to provide any further guarantees with respect to loans made to the Company.&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Sections 5.4</font> and <font style="text-decoration:underline;">5.5.2</font>, if requested by the Board pursuant to a written request made to all, but not less than all, of the Shareholders, each of BioAmber Lux and Mitsui shall have the right, but not the obligation, to provide additional guarantees in favor of Lenders in respect of further loans provided by such Lenders to the Company, in each case within thirty&#160;(30) days of the date of such request (or such longer period as the Board may determine, which period shall apply equally to all Shareholders); <font style="font-style:italic;">provided</font>, that (i)&#160;in the event that the respective guarantees provided by BioAmber and Mitsui in respect of the Comerica Loan Agreement expire or are terminated, such parties shall be required, if so requested by the Board, to provide the Company with additional capital contributions or parent company guarantees up to the amount of such expired or terminated guarantees in accordance with their then respective Pro Rata Shares, (ii)&#160;any such guarantees requested by the Board shall be allocated between the Shareholders in accordance with their respective Pro Rata Shares and (iii)&#160;if and to the extent that any such Lender so requests (and the BioAmber Parties agree), such guarantees shall be provided by BioAmber on behalf of BioAmber Lux, which guarantees so provided by BioAmber shall be deemed to have been allocate<a name="_DV_M198"></a>d to BioAmber Lux&#8217;s Pro Rata Share.<a name="_DV_M206"></a>&nbsp;&nbsp;In the event that (x)&#160;either Shareholder provides less than its full Pro Rata Share of any such additional loan guarantee within the applicable period therefor and (y)&#160;the other Shareholder contributes its full Pro Rata Share of such additional loan guarantee within the applicable period therefor, then such fully guaranteeing Shareholder shall have the right, but not the obligation, to provide an additional loan guarantee in favor of the relevant Lender(s) up to the loan<a name="_DV_C6"></a> guarantee amount not provided by the other Shareholder.&nbsp;&nbsp;For the guarantees in favor of Lenders that Mitsui and BioAmber Lux (and/or BioAmber) provide according to the terms of this <font style="text-decoration:underline;"><a name="_DV_M199"></a>Section 5.1.4</font><a name="_DV_C7"></a>, the Company shall pay to <a name="_DV_M200"></a>each of Mitsui and BioAmber Lux (<a name="_DV_M201"></a>and/or BioAmber) an annual fee <a name="_DV_C10"></a>in respect of <a name="_DV_M202"></a>their respective<a name="_DV_C12"></a> guarantees <a name="_DV_M203"></a>of the loans<a name="_DV_C13"></a> provided by <a name="_DV_M204"></a>such Lenders in the amounts and pursuant to such terms as <a name="_DV_C14"></a>Mitsui and BioAmber<a name="_DV_M205"></a> mutually agree (including, with respect to Mitsui, as provided in the Reimbursement Agreements in relation to the loans referenced therein).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M207"></a><a name="_Ref301963803"></a><a name="_Ref174506132"></a><a name="_Ref174506133"></a>5.1.5<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Mitsui Maximum Commitment</font>.&nbsp;&nbsp;For the avoidance of doubt, notwithstanding anything herein to the contrary, in no event shall Mitsui be obligated to provide capital contributions, guarantees or other financial support to or on behalf of the Company pursuant to this <font style="text-decoration:underline;">Section 5.1</font>, <font style="text-decoration:underline;">Section 5.2</font> or otherwise if and to the extent that the amount of such capital contributions or exposure under such guarantees or other financial support, together with all amounts previously financed by (and not repaid to) Mitsui and all amounts for which Mitsui is then currently exposed with respect to guarantees or other financial support, exceed $45,600,000 (the &#8220;<font style="font-weight:bold;font-style:italic;">Mitsui Maximum Commitment</font>&#8221;).&nbsp;&nbsp;For further clarity, however, Mitsui shall have the right, </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">15</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">in its sole discretion, to provide up to its Pro Rata Share of any financial support requested by the Board in excess of the Mitsui Maximum Commitment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443470727"></a>5.1.6<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Pro Rata Shares</font>.&nbsp;&nbsp;In exchange for the amount of the Second Additional Mitsui Capital Contribution, the Company shall issue to Mitsui additional Shares at the price set forth in <font style="text-decoration:underline;">Section&#160;5.3.1</font>.&nbsp;&nbsp;The respective Pro Rata Shares of the Shareholders shall be proportionally adjusted to reflect the additional Shares issued to Mitsui in exchange for the amount of the Second Additional Mitsui Capital Contribution.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M208"></a><a name="_Ref301959732"></a><a name="_Toc444101295"></a>5.2<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Additional Financial Contributions</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M209"></a><a name="_Ref174536336"></a><a name="_Ref164423118"></a><a name="_DV_M210"></a>5.2.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Additional Contributions</font>.&nbsp;&nbsp;If the Board determines that the Company requires financial contributions in excess of the commitments set forth in <font style="text-decoration:underline;">Section 5.1</font>, in the form of equity, loans, guarantees or otherwise (any such financial contribution, an &#8220;<font style="font-weight:bold;font-style:italic;">Additional Contribution</font>&#8221;), then the President, on behalf of the Board, shall provide written notice thereof to each Shareholder, setting forth the nature, amount and other relevant terms of the Additional Contribution (a &#8220;<font style="font-weight:bold;font-style:italic;">Contribution Notice</font>&#8221;); <font style="font-style:italic;">provided</font>, that in the event that the President does not provide such Contribution Notice to each Shareholder within five (5) business days from the date of the relevant Board resolution, then any Director shall be entitled to provide such Contribution Notice to each Shareholder on behalf of the Board (which Contribution Notices shall be effective as if they had been provided by the President).&nbsp;&nbsp;The Shareholders shall thereupon engage in good faith discussions in respect of such Additional Contribution, including the terms and intended purpose thereof, for a period of fifteen<font style="font-weight:bold;"> </font>(15) days (or such other period as the Shareholders may mutually agree) after the date the Board delivered to the Shareholders the relevant Contribution Notice, and the Board shall implement any agreement in respect of such Additional Contribution that the Shareholders may thereby reach.&nbsp;&nbsp;Subject to the preceding sentence, each Shareholder shall have the right, but not the obligation, to contribute up to its Pro Rata Share of any Additional Contribution, within thirty&#160;(30) days after the expiration of the fifteen<font style="font-weight:bold;"> </font><a name="_DV_M210"></a>(15) day period (or such other period as the Shareholders may mutually agree) referred to in the preceding sentence (subject to such additional period of time as may be necessary to determine the applicable per Share price in accordance with <font style="text-decoration:underline;">Section 5.3.2</font>, if applicable).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M211"></a><a name="_Ref174535686"></a>5.2.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Shortfall</font>.&nbsp;&nbsp;In the event that (i) the Board issues a Contribution Notice for an Additional Contribution in the form of equity, (ii) either Shareholder contributes less than its full Pro Rata Share of such Additional Contribution within the applicable period therefor and (iii) <font style="font-size:11pt;"> </font>the other Shareholder contributes its full Pro Rata Share of such Additional Contribution within the applicable period therefor, then such contributing Shareholder shall have the right, but not the obligation, to provide funds to the Company up to the amount not contributed by the other Shareholder.&nbsp;&nbsp;In such event, the Company shall issue additional Shares to the contributing Shareholder, and the respective Pro Rata Shares of the Shareholders shall be adjusted, in accordance with <font style="text-decoration:underline;">Section 5.3</font>.&nbsp;&nbsp;For the avoidance of doubt, any reduction in Mitsui&#8217;s Pro Rata Share pursuant to this <font style="text-decoration:underline;">Section 5.2.2</font> <font style="color:#000000;">shall proportionally reduce Mitsui&#8217;s economic right to receive dividends or other distributions from the Company </font><font style="font-style:italic;color:#000000;">but</font><font style="color:#000000;"> shall not reduce or otherwise affect in any manner whatsoever any other rights of Mitsui hereunder, including its rights under </font><font style="text-decoration:underline;color:#000000;">Section 8</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">16</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M212"></a><a name="_Toc444101296"></a><a name="_Ref302054793"></a><font style="text-decoration:underline;">Share Valuation</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Except as otherwise provided in <font style="text-decoration:underline;">Sections&#160;5.1.6</font>, <font style="text-decoration:underline;">5.6.4(e)</font> and the last sentence of <font style="text-decoration:underline;">Section&#160;5.6.5</font>:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M213"></a><a name="_Ref443041831"></a><a name="_DV_M214"></a><a name="_Ref248898724"></a>5.3.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Valuation Pre-Operational Date</font><a name="_DV_M214"></a><a name="_Ref248898724"></a>.&nbsp;&nbsp;For any capital call made by the Board to be funded prior to the Operational Date, the price per Share to be issued pursuant to such capital call shall be equal to the per Share purchase price for the Shares acquired by Mitsui and BioAmber Lux pursuant to the Subscription Agreements, which price is equal to $10 per Share.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M215"></a><a name="_Ref301969719"></a><a name="_Ref301972815"></a><a name="_DV_C16"></a><a name="_Ref252350565"></a><a name="_DV_M216"></a><a name="_DV_M217"></a>5.3.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Valuation Post-Operational Date</font><a name="_DV_C16"></a><a name="_Ref252350565"></a>.&nbsp;&nbsp;<a name="_DV_M216"></a>For any capital call made by the Board to be funded on or after the Operational Date, the Shareholders shall discuss and negotiate in good faith on a valuation of the Company (as of the date of the applicable capital call notice) for the purpose of determining the price per Share to be issued in the applicable capital call (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Company Valuation</font>&#8221;), and such price per Share shall be equal to the quotient of such Company Valuation and the total number of then-issued and outstanding Shares (the &#8220;<font style="font-weight:bold;font-style:italic;">Financing Share Price</font>&#8221;).&nbsp;&nbsp;If the Shareholders are unable to agree on the Company Valuation within thirty&#160;(30) days, or such other period as agreed by the Shareholders, after receipt of the applicable capital call notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Valuation Deadline</font><a name="_DV_M217"></a>&#8221;), then the Financing Share Price shall be equal to the Fair Market Value of the Shares as of the date of such capital call notice and shall be determined by an appraisal as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M218"></a><a name="_DV_M219"></a><a name="_Ref301972939"></a>(a)<font style="margin-left:144pt;"></font>the Shareholders shall discuss in good faith with a view to agreeing on the appointment of an independent investment bank or independent accounting firm of recognized international standing (the &#8220;<font style="font-weight:bold;font-style:italic;">Appraiser</font>&#8221;), and if the Shareholders reach agreement on the appointment of the Appraiser within thirty&#160;(30) days after the Valuation Deadline, such Company Valuation shall be determined by the Appraiser in accordance with clauses (b) and (c) immediately below.&nbsp;&nbsp;If the Shareholders are unable to reach agreement on and appoint the Appraiser within thirty&#160;(30) days after the Valuation Deadline, then the Appraiser shall be appointed by the International Centre for Expertise in accordance with the provisions for the appointment of experts under the Rules for Expertise of the ICC.&nbsp;&nbsp;The cost, fees and expenses incurred in connection with the appointment of the Appraiser shall be borne equally between the Shareholders.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M220"></a><a name="_Ref248596093"></a>(b)<font style="margin-left:144pt;"></font>The parties agree that the basis for determining the Fair Market Value shall be the price that would be paid in an arm&#8217;s-length sale between an informed and willing seller under no compulsion to sell and an informed and willing buyer under no compulsion to buy.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M221"></a>(c)<font style="margin-left:144pt;"></font>The Appraiser shall submit its appraisal report to each of the Shareholders and the Company within thirty&#160;(30) days after the date of its appointment.&nbsp;&nbsp;The appraisal set forth in such appraisal report shall be the definitive Fair Market Value of the Shares, and it shall be final and binding on the Shareholders for the purposes of this <font style="text-decoration:underline;">Section 5.3.2</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">17</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M222"></a><a name="_Toc444101297"></a><a name="_Ref174529685"></a><a name="_Ref174597493"></a><font style="text-decoration:underline;">Guarantees</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M223"></a><a name="_DV_M224"></a><a name="_Ref301971436"></a><a name="_DV_M223"></a><a name="_DV_M224"></a><a name="_Ref301971436"></a>.&nbsp;&nbsp;Any obligations of the Shareholders (or BioAmber, as the case may be) in respect of third parties (whether arising from loan guarantees pursuant to <font style="text-decoration:underline;">Section 5.1.4</font> or otherwise) shall be on a several or individual basis and not on a joint or collective basis, and no Shareholder shall be liable to third parties in respect of any obligation of any other Shareholder (or BioAmber, as the case may be).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101298"></a>5.5<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Comerica Loan Agreement</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443067298"></a>5.5.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Comerica Loan Agreement Modifications</font>.&nbsp;&nbsp;BioAmber, Mitsui and the Company shall promptly from the date hereof cooperate in good faith to engage in (or continue their) negotiations with the Agent and the Lenders under the Comerica Loan Agreement, as applicable, to effect the following amendments, modifications and waivers with respect to such loan agreement, with a target date to implement such amendments, modifications and waivers by March 31, 2016:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(a)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Termination of Share Pledges</font>.&nbsp;&nbsp;Terminate (i)&#160;the Pledge and Assignment Agreement, dated as of May 12, 2015, between BioAmber Lux and the Agent, with respect to the pledge and assignment of the Shares held by BioAmber Lux in favor of the Agent (acting on behalf of the Lenders under the Comerica Loan Agreement), and cancel the security interest in such Shares created thereunder; and (ii)&#160;the Pledge and Assignment Agreement, dated as of May 12, 2015, between Mitsui and the Agent, with respect to the pledge and assignment of the Shares held by&nbsp;&nbsp;Mitsui in favor of the Agent (acting on behalf of the Lenders under the Comerica Loan Agreement), and cancel the security interest in such Shares created hereunder;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(b)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BioAmber Insolvency Event</font>.&nbsp;&nbsp;Provide that an Insolvency Event (as such term is defined in the Comerica Loan Agreement) with respect to BioAmber will not constitute an Event of Default (as such term is defined in the Comerica Loan Agreement); and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(c)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Restricted Cash Covenants</font>.&nbsp;&nbsp;A waiver of all of the Company&#8217;s obligations under the Comerica Loan Agreement, and any document ancillary thereto, with respect to the Debt Service Reserve Account, the Maintenance Reserve Account, the Cost Overrun Account and the Punch List Reserve Sub-Account, as such terms are defined respectively in Sections 5.2, 5.3, 5.4 and 5.5 of the Comerica Loan Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443294389"></a><a name="_Ref443067483"></a>5.5.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Comerica Loan Agreement Guarantee</font><a name="_Ref443067483"></a>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443473065"></a>(a)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Mitsui Loan Guarantee</font>.&nbsp;&nbsp;Mitsui may, in its sole discretion (it being understood that Mitsui shall not have any obligation to offer any such undertaking, and the making of such offer shall not be a condition to the parties&#8217; commitment hereunder to negotiate such amendments, modifications and waivers), as an inducement for the Agent and the Lenders under the Comerica Loan Agreement to execute the amendments, modifications and waivers with respect to the Comerica </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">18</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Loan Agreement describ</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ed in </font><font style="text-decoration:underline;">Section&#160;</font><font style="text-decoration:underline;">5.5.1</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, undertake to guarantee all of the Secured Obligations (as such term is defined in the Comerica Loan Agreement) under the Comerica Loan Agreeme</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">nt, pursuant to a guarantee agreement in form and substance mutually agreeable to the Agent, the Lenders under the Comerica Loan Agreement and Mitsui.&#160; If Mitsui so undertakes to assume such guarantee under the Comerica Loan Agreement, BioAmber and the Com</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">pany shall cooperate with Mitsui to effect such guarantee assumption.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(b)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Guarantee Fee</font>.&nbsp;&nbsp;In consideration of Mitsui&#8217;s assumption of such additional guarantee obligation in accordance with <font style="text-decoration:underline;">Section&#160;5.5.2(a)</font>, the Company shall pay to Mitsui an annual guarantee fee equal to 1.0% of the aggregate amount of the additional guarantee obligation with respect to the Comerica Loan Agreement assumed by Mitsui as provided herein, which guarantee fee shall be paid by the Company to Mitsui in a manner consistent with the payment of the existing guarantee fees payable by the Company to Mitsui pursuant to the Reimbursement Agreements.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(c)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Additional Modifications to Comerica Loan Agreement</font>.&nbsp;&nbsp;Furthermore, the parties acknowledge and agree that Mitsui may request additional amendments and modifications to the Comerica Loan Agreement, to conform its terms and conditions to those accepted by other lenders under other loan instruments guaranteed by Mitsui, in which case the parties shall endeavor to discuss in good faith such additional proposed amendments and modifications and to engage in negotiations with the Agent and the Lenders under the Comerica Loan Agreement, as applicable, in order to implement them.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101299"></a><a name="_Ref443068026"></a><font style="text-decoration:underline;">Convertible Loan</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443067862"></a>5.6.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Convertible Loan</font>.&nbsp;&nbsp;If Mitsui guarantees all of the Secured Obligations under the Comerica Loan Agreement pursuant to <font style="text-decoration:underline;">Section&#160;5.5.2</font>, then in connection with any (x)&#160;Event of Default by the Company under the Comerica Loan Agreement or (y)&#160;Trigger Event, Mitsui shall have the right (but not the obligation) to provide to the Company (and the Company shall accept) a convertible loan to enable the Company to repay all of the amounts outstanding under the Comerica Loan Agreement (the &#8220;<font style="font-weight:bold;font-style:italic;">Convertible Loan</font>&#8221;), as further provided herein.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443295328"></a>5.6.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Trigger Event</font>.&nbsp;&nbsp;&nbsp;&nbsp;As used in this <font style="text-decoration:underline;">Section&#160;5.6</font>, a &#8220;<font style="font-weight:bold;font-style:italic;">Trigger Event</font>&#8221; shall be deemed to have occurred at any time if, within thirty (30) days, (x)&#160;a shortage in the Company&#8217;s cash position is expected to occur (<font style="font-style:italic;">i.e.</font>, the Company is expected to lack sufficient cash to cover its payment commitments) or (y)&#160;the Company is expected to be in breach or default (including with respect to any of its payment obligations, financial covenants or any other covenants that require it to satisfy minimum cash requirements) under any of its loan agreements or to be in breach or violate any other Contract to which it is a party (including supply agreements and service agreements), in each case in the absence at such time of (i)&#160;sufficient effective waivers granted by Lenders, contractors, suppliers or other relevant counterparties in respect of which the Company has payment commitments that avoid the occurrence of an event of default under the loan </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">19</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">documents with the Lenders</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><sup style="font-size:85%; vertical-align:top"> </sup></font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> and a breach or violation of any other Contract to which the Company is a party (including supply agreements and service agreements); (ii)&#160;sufficient additional funding of the Company provided by the Shareholders based on their respective Pro Rata Shares</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">that avoids the occurrence of an event of default under the loan documents with the Lenders</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><sup style="font-size:85%; vertical-align:top"> </sup></font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> and a breach or violation of any other Contract to which the Company is a party (including supply agreements and service agreements); or (iii)&#160;an existing, feasibl</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">e refinancing plan of the Company that is expected to be implemented within a timeframe that avoids the occurrence of an event of default under the loan documents with the Lenders</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><sup style="font-size:85%; vertical-align:top"> </sup></font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> and a breach or violation of any other Contract to which the Company is a p</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">arty (including supply agreements and service agreements).&nbsp;&nbsp;For clarity, a Trigger Event shall not be deemed to have occurred if any of the events referenced in the foregoing clause (i), (ii) or (iii) has occurred.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.6.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Information</font>.&nbsp;&nbsp;&nbsp;&nbsp;The Company shall provide to each of BioAmber and Mitsui with sufficient information (including cash projections and detailed information and documents supporting such projections) for each of BioAmber and Mitsui to be able to determine whether a Trigger Event exists.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.6.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Terms of Convertible Loan</font>.&nbsp;&nbsp;The Convertible Loan provided by Mitsui to the Company as contemplated hereby (if any) shall be in accordance with the following terms (and such other terms and conditions that Mitsui and BioAmber may agree to):</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(a)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Use of Proceeds</font>.&nbsp;&nbsp;The proceeds of the Convertible Loan shall be used by the Company to repay all of the amounts outstanding under the Comerica Loan Agreement.&nbsp;&nbsp;For clarity, the Company shall as promptly as possible apply the proceeds from the Convertible Loan to repay (including prepaying prior to the applicable maturity date, in accordance with the terms of the Comerica Loan Agreement) all of the amounts outstanding under the Comerica Loan Agreement;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(b)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Interest Rate</font>.&nbsp;&nbsp;To be mutually agreed by Mitsui and BioAmber, based on the range between the interest rate in effect at the time under the Comerica Loan Agreement and the rate offered by BDC;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(c)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Repayment Schedule</font>.&nbsp;&nbsp;The repayment schedule of the Convertible Loan shall not be more onerous to the Company than the repayment schedule of the Comerica Loan Agreement which such Convertible Loan is intended to replace;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443068473"></a>(d)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Timing of Conversion</font>.&nbsp;&nbsp;The amounts outstanding under the Convertible Loan shall be converted (partly or wholly, at Mitsui&#8217;s election) into Shares, at Mitsui&#8217;s option, exercisable by wr<a name="_Ref443068473"></a>itten notice to BioAmber and the Company, by the end of each calendar quarter until the end of calendar year 2018;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443467192"></a>(e)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Share Valuation</font>.&nbsp;&nbsp;Any Shares issued by the Company in connection with a conversion of the amounts outstanding under the Convertible Loan shall be issued at a price per Share equal to the lower of (x)&#160;$10 per Share and (y)&#160;the Fair Market Value of such Shares; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">20</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(f)</font><font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Security</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;In connection with its provision of the Convertible Loan to the Company and the repayment with the proceeds thereof of the</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> amounts outstanding under the Comerica Loan Agreement, Mitsui shall be entitled to receive and be vested with (and the parties shall take all action necessary to so provide and vest on Mitsui) all of the Lenders&#8217; right, title and interest in the Comerica </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Loan Agreement, the amounts due thereunder, all security and guarantees therefor and all collateral subject to a security interest pursuant to such security, in each case as presently in effect (including a perfected first priority security interest in and</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> pledge of the Shares held by the BioAmber Parties (or their Permitted Transferees)).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443295942"></a>5.6.5<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Additional BioAmber Lux Capital Contribution</font>.&nbsp;&nbsp;Provided that either (a)&#160;Mitsui has provided to the Company the Second Additional Mitsui Capital Contribution or (b)&#160;Mitsui&#8217;s Pro Rata Share has reached forty percent (40%) or more, then in connection with the making of the Convertible Loan, BioAmber Lux shall have the right (subject to any applicable Lenders&#8217; consent, including with respect to the use of proceeds from such capital contribution as provided in the following sentence) to provide to the Company an additional capital contribution at the end of each calendar quarter during the six (6) month period following the disbursement of the Convertible Loan to the Company in an aggregate amount for all such capital contributions equal to up to (x)&#160;BioAmber Lux&#8217;s then-current Pro Rata Share (as the same may be adjusted, including as a result of the issuance of additional Shares to Mitsui upon any conversion of the Convertible Loan) <font style="font-style:italic;">multiplied</font> <font style="font-style:italic;">by</font> (y)&#160;the then-outstanding aggregate amount of the Convertible Loan.&nbsp;&nbsp;The proceeds of any such capital contribution by BioAmber Lux to the Company shall be used by the Company to repay the amounts outstanding under the Convertible Loan.  Any Shares issued by the Company to BioAmber Lux in connection with such additional capital contribution shall be issued at a price per Share equal to the conversion price for Shares issuable under the Convertible Loan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101300"></a>5.7<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">BDC Credit Facility</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443061843"></a>5.7.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BDC Letter of Intent</font>.&nbsp;&nbsp;Prior to the date hereof, Mitsui delivered to the Company a signed Shareholders&#8217; consent confirming to the Company its acceptance of the Letter of Intent to finance, dated as of January 26, 2016, issued to the Company by BDC (the &#8220;<font style="font-weight:bold;font-style:italic;">BDC Letter of Intent</font>&#8221;, and the financing contemplated by the BDC Letter of Intent,&nbsp;&nbsp;the &#8220;<font style="font-weight:bold;font-style:italic;">BDC Credit Facility</font>&#8221;); <font style="font-style:italic;">provided</font>, that such acceptance is subject to the satisfaction of each of the following conditions:&nbsp;&nbsp;(i)&#160;such credit facility shall not require the provision of any guarantee or similar credit support by BioAmber or Mitsui; (ii)&#160;an insolvency event with respect to BioAmber shall not constitute an event of default under such credit facility; (iii)&#160;such credit facility shall allow for the provision of the Convertible Loan and the additional capital contribution by BioAmber Lux to the Company as contemplated by <font style="text-decoration:underline;">Section&#160;5.6</font> (including the use of proceeds from such capital contribution by the Company to repay the amounts outstanding under the Convertible Loan); (iv)&#160;the aggregate principal amount under such credit facility shall not exceed $10,000,000; (v)&#160;such credit facility shall acknowledge the existence of this Agreement and the rights of the parties hereunder, with the rights of BDC under such credit facility being subject to such rights; and (vi)&#160;the definitive terms and conditions of such credit facility shall not be less favorable to the Company than those set forth in the BDC Letter of Intent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">21</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443296054"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.7.2</font><font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BDC Definitive Agreements</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Upon written request by the Company, Mitsui shall review the </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">definitive</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> agreement implementing the BDC Credit Facility (the &#8220;</font><font style="font-weight:bold;font-style:italic;">BDC Definitive Agreements</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221;) to confirm the following: (a)&#160;the te</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">rms and conditions of the BDC Definitive Agreements are not less favorable to the Company than those set forth in the BDC Letter of Intent; and (b) the terms and conditions of the BDC Definitive Agreements are consistent with the BDC Letter of Intent and i</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">tems (i) through (vi) of </font><font style="text-decoration:underline;">Section&#160;</font><font style="text-decoration:underline;">5.7.1</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Provided that (x)&#160;the Company delivers to Mitsui such request for confirmation by no later than March 31, 2016, and (y)&#160;Mit</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">sui thereafter confirms that all of the conditions set forth in the preceding clauses (a) and (b) have been satisfied, then Mitsui shall deliver to the Company a signed Shareholders&#8217; consent confirming to the Company its acceptance of the BDC Definitive Ag</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">reements.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M225"></a><a name="_DV_M226"></a><a name="_Toc444101301"></a><a name="_Ref161806127"></a><a name="_Ref301965330"></a>NON-FINANCIAL CONTRIBUTIONS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M227"></a><a name="_Ref444158449"></a><a name="_Toc444101302"></a><a name="_Ref301972264"></a><font style="text-decoration:underline;">BioAmber Non-Financial Contributions</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M228"></a>.&nbsp;&nbsp;BioAmber shall make available to the Company the following functions and capabilities:&nbsp;&nbsp;(i) application development and technical sales support; (ii) hiring and training of plant<a name="_DV_M228"></a> personnel; and (iii) oversight of the EPC Contract.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M229"></a><a name="_Ref444158656"></a><a name="_Toc444101303"></a><a name="_Ref301972280"></a><font style="text-decoration:underline;">Mitsui Non-Financial Contributions</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M230"></a>.&nbsp;&nbsp;Mitsui shall make available to the Company the following functions and capabilities:&nbsp;&nbsp;(i) know-how regarding shipping and logistics, warehousing, credit checks, frei<a name="_DV_M230"></a>ght insurance, and trade finance globally; (ii) facilitation of potential sales in Asia; and (iii) support in implementing the Company&#8217;s internal control systems.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M231"></a><a name="_Toc444101304"></a><a name="_Ref174521492"></a><a name="_Ref174597104"></a><font style="text-decoration:underline;">Provision of Non-Financial Contributions</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The functions and capabilities referred to in <font style="text-decoration:underline;">Sections 6.1</font> and <font style="text-decoration:underline;">6.2</font> shall be provided by each of BioAmber and Mitsui to the Company (a) by appointing appropriate Directors at no cost to the Company (other than as set forth in <font style="text-decoration:underline;">Section 8.2.12)</font>; (b) by seconding to the Company personnel of such party, on terms, including costs to be charged to the Company, to be agreed (subject to <font style="text-decoration:underline;">Section 8.1.3</font>); or (c) as BioAmber, Mitsui and the Company may otherwise agree.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M232"></a><a name="_Toc444101305"></a>REDUCTION/TERMINATION OF CONTRIBUTIONS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M233"></a><a name="_Toc444101306"></a><a name="_Ref301974661"></a><font style="text-decoration:underline;">Reduction/Termination of Contributions</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M234"></a>.&nbsp;&nbsp;In the event of a reduction of any Shareholder&#8217;s Pro Rata Share, any obligation of such Shareholder (or BioAmber, as applicable) to provide (a) loan guarantees or (b) any other form of financial support (including loans) to the Company shall be proportionally reduced or terminated, as applicable, to the extent of any such reduction (it being understood that any BioAmber obligation to provide any financial support to the Company shall be so reduced or terminated to the extent of any reduction in BioAmber Lux&#8217;s Pro Rata Share)<a name="_DV_M234"></a>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M235"></a><a name="_Toc444101307"></a><a name="_Ref301974677"></a><font style="text-decoration:underline;">Termination of Secondments/Assignments</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;In the event that a Shareholder shall hold no Equity Securities of the Company, any personnel then seconded or otherwise assigned to the Company by such Shareholder shall be released from such secondment or assignment, simultaneously with, or as promptly as practicable after, the date on which such Shareholder ceases to hold any such Equity Securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">22</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M236"></a><a name="_Toc444101308"></a><font style="text-decoration:underline;">Action by the Parties</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_C18"></a><a name="_DV_M237"></a><a name="_DV_M238"></a><a name="_DV_C20"></a><a name="_DV_M239"></a><a name="_DV_M240"></a>.&nbsp;&nbsp;If and to the extent required pursuant to such Sections, the parties shall take all action necessary to effect the reduction/termination of financial support obligations and the release of seconded/assigned personnel contemplat<font style="color:#000000;">ed by </font><font style="text-decoration:underline;color:#000000;">Sections 7.1</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">7.2</font><font style="color:#000000;"> (including by providing replacement guarantees or ot</font><a name="_DV_C18"></a>herwise).&nbsp;&nbsp;In furtherance, and without<a name="_DV_M237"></a> limiting the generality, of the foregoing, the parties also agree<font style="color:#000000;"><a name="_DV_M238"></a> that if Mitsui shall hold no Equity Securities of the Company, then BioAmber Lux hereby undertakes to deploy its best efforts in order to obtain from the concerned </font><a name="_DV_C20"></a>Lenders a <a name="_DV_M239"></a>complete releas<font style="color:#000000;"><a name="_DV_M240"></a>e for any guarantee granted by Mitsui in connection with any loan provided by such Lenders to the Company</font>.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M241"></a><a name="_DV_M242"></a><a name="_Ref301972587"></a><a name="_Ref302483888"></a><a name="_Toc444101309"></a><a name="_DV_M243"></a><a name="_DV_M244"></a><a name="_DV_M245"></a><a name="_DV_M243"></a>MANAGEMENT<a name="_DV_M244"></a> <a name="_DV_M245"></a>OF THE COMPANY</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M246"></a><a name="_Toc444101310"></a><a name="_Ref174589400"></a><a name="_Ref301976315"></a><a name="_Ref174521196"></a><a name="_Ref174529779"></a><a name="_Ref243821470"></a>8.1<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Shareholders</font><a name="_Ref243821470"></a>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M247"></a><a name="_DV_M248"></a>8.1.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Voting</font>.&nbsp;&nbsp;Each Shareholder shall vote its Shares at all ordinary or extraordinary meetings of Shareholders, an<a name="_DV_M248"></a>d shall take all other actions necessary, to give effect to the provisions of this Agreement.&nbsp;&nbsp;Except as otherwise provided for herein or by Applicable Law, the adoption of any resolution at a Shareholders&#8217; meeting shall require the affirmative vote of a simple majority of the then-issued and outstanding voting Shares.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M249"></a><a name="_Ref301984505"></a><a name="_DV_M250"></a><a name="_DV_M251"></a><a name="_DV_M253"></a>8.1.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;"><a name="_DV_M250"></a>Actions Requiring Unanimous Shareholder Consent Subject to BioAmber Lux&#8217;s Final Approval</font>.&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Section&#160;18.1.2</font>, the following actions are subject to, and the Company shall not take any <a name="_DV_M251"></a><a name="_DV_M253"></a>such action without first obtaining, the prior written consent of each Shareholder:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443473658"></a><a name="_DV_M254"></a>(a)<font style="margin-left:144pt;"></font>the approval of any annual budget of the Company (or any modification thereof), it being understood that, in any event, an annual budget shall include any capital expenditure only to the extent it is demonstrated with sufficient supporting information or documentation that the same is (i)&#160; in the ordinary course of business of the Company in light of relevant industrial standards and the Company&#8217;s business plan and (ii)&#160;need<a name="_DV_M254"></a>ed in order to maintain the Initial Plant in an operational mode and execute the annual budget of the Company;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443468248"></a><a name="_DV_M255"></a><a name="_DV_M256"></a><a name="_DV_M257"></a><a name="_Ref302552561"></a>(b)<font style="margin-left:144pt;"></font>the execution of any raw material or utility supply Contract for the Initial Plant, for which it is demonstrated with sufficient supporting information or documentation that it is in the ordinary course of business of the Company in light of relevant industrial standards and the Company&#8217;s business plan<a name="_DV_M255"></a><a name="_DV_M256"></a><a name="_DV_M257"></a><a name="_Ref302552561"></a>; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443293228"></a><a name="_DV_M258"></a>(c)<font style="margin-left:144pt;"></font>the hiring and firing of personnel in management positions at the Initial Plant (subject to Mitsui&#8217;s right to nominate the CCO, as provided in <font style="text-decoration:underline;">Section&#160;8.3.2</font>), and the approval of annual performance reviews and the compensation of such personnel.&nbsp;&nbsp;For these purposes, &#8220;management positions&#8221; consists of the President of the Initial Plant and all persons reporting directly to the President, including the manager of the Initial Plant (the &#8220;<font style="font-weight:bold;font-style:italic;">Plant Manager</font><a name="_DV_M258"></a>&#8221;);</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">23</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-variant: normal;"><a name="_Ref443291854"></a><font style="font-style:italic;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-variant: normal;">provided</font><font style="font-style:normal;">, that (except in the event contemplated by </font><font style="text-decoration:underline;font-style:normal;">Section&#160;</font><font style="text-decoration:underline;font-style:normal;">8.1.4</font><font style="font-style:normal;">, in which case the following provisions of this proviso shall not apply) if the Shareholders are unable t</font><font style="font-style:normal;">o agree on any such action within thirty&#160;(30) days after the Board or, in the event that a majority of the Directors present at a duly constituted meeting of the Board fails to approve such submission,</font><font style="font-style:normal;"> any Director</font><font style="font-style:normal;"> submits, in writing, such action for appr</font><font style="font-style:normal;">oval of the Shareholders (which submission shall set forth, in reasonable detail, a description of the proposed action, the purpose and other relevant terms thereof), such proposed action shall be submitted by the Shareholders for further discussion to the</font><font style="font-style:normal;">ir respective designated senior representatives, who shall have authority to reach an agreement on behalf of the applicable Shareholder.&nbsp;&nbsp;If such designated senior representatives remain unable to reach an agreement within thirty&#160;(30) days after the date o</font><font style="font-style:normal;">n which the proposed action was submitted to them, BioAmber Lux shall have the right to approve, and upon receipt of such approval the Company shall adopt, such action without Mitsui&#8217;s approval (the &#8220;</font><font style="font-weight:bold;">BioAmber Right to Approve</font><font style="font-style:normal;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M259"></a><a name="_DV_M260"></a><a name="_Ref301979686"></a><a name="_Ref174529802"></a><a name="_DV_M261"></a>8.1.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Actions Requiring Unanimous Shareholder Consent</font>.&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Section 18.1.2</font><a name="_DV_M261"></a>, the following actions are subject to, and the Company shall not take any such action without, the prior written consent of each Shareholder:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M262"></a>(a)<font style="margin-left:144pt;"></font>any change in any service or royalty fee paid by the Company to B<a name="_DV_M262"></a>ioAmber or any Affiliate thereof;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M263"></a>(b)<font style="margin-left:144pt;"></font>subject to <font style="text-decoration:underline;">Section 19</font><a name="_DV_M263"></a>, the dissolution, liquidation or winding up of the Company (or any action for such purpose);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M264"></a>(c)<font style="margin-left:144pt;"></font>the sale or purchase by the Company of any asset for an amount in excess of five hundred thousand Dollars (<a name="_DV_M264"></a>$500,000) or that is otherwise material to the Company (other than raw materials purchased, or inventory sold, in the ordinary course of business of the Company or as otherwise contemplated in an approved business plan or annual budget of the Company);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M265"></a>(d)<font style="margin-left:144pt;"></font>any<a name="_DV_M265"></a> change in the scope of the Business;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M266"></a>(e)<font style="margin-left:144pt;"></font><a name="_DV_M266"></a>any change in the accounting principles or practices of the Company;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M267"></a>(f)<font style="margin-left:144pt;"></font>any transaction between the Company and any Shareholder or Affiliate thereof other than (i)&#160;the issuance of Shares to the Shareholders pursuant to th<a name="_DV_M267"></a>e terms of the Subscription Agreements or this Agreement, as applicable, and (ii)&#160;the transactions contemplated by the Ancillary Agreements in accordance with the respective terms and conditions thereof;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M268"></a>(g)<font style="margin-left:144pt;"></font>any borrowing or other incurrence of indebtedness of<a name="_DV_M268"></a> any kind, or the granting of any security or guarantees (unless contemplated by an approved business plan or annual budget of the Company);</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">24</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M269"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(h)</font><font style="margin-left:144pt;"></font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M269"></a>the making of loans or provision of guarantees or other financial support by the Company in favor of third parties;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M270"></a>(i)<font style="margin-left:144pt;"></font><a name="_DV_M270"></a>commencing, or making any significant decision relating to, any Proceeding outside the ordinary course of business of the Company;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M271"></a>(j)<font style="margin-left:144pt;"></font><a name="_DV_M271"></a>any change to the Company&#8217;s Charter Documents;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M272"></a>(k)<font style="margin-left:144pt;"></font>any reorganization, amalgamation, merger or similar transaction by or involvi<a name="_DV_M272"></a>ng the Company;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(l)<font style="margin-left:144pt;"></font>the closure of, or cessation of activities at, the Initial Plant (other than temporary stoppages in the ordinary course of business of the Company);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(m)<font style="margin-left:144pt;"></font>any change to the Marketing Policy;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443047357"></a>(n)<font style="margin-left:144pt;"></font>the entering into any Contract by the Company relating <a name="_Ref443047357"></a>to sales, marketing and/or distribution with a term longer than one (1) year;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M252"></a>(o)<font style="margin-left:144pt;"></font>the entering into any Contract (other than the EPC Contract, which is subject to clause (p) immediately below) by the Company to effect any capital expenditure (except to the extent such capital expenditure is included in an annual budget of the Company approved in accordance with <font style="text-decoration:underline;">Section&#160;8.1.2(a)</font>), for expansion, improvement or any other r<a name="_DV_M252"></a>eason;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(p)<font style="margin-left:144pt;"></font>the selection of the EPC Firm and the terms and conditions of the EPC Contract (and any amendment thereof or waiver of any right thereunder); </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(q)<font style="margin-left:144pt;"></font>any approval and modification of the Company&#8217;s business plan; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(r)<font style="margin-left:144pt;"></font>the execution of any raw material or utility supply Contract for the Initial Plant (other than any such Contract for which it is demonstrated with sufficient supporting information or documentation that it is in the ordinary course of business of the Company in light of relevant industrial standards and the Company&#8217;s business plan, which shall be subject to approval in accordance with <font style="text-decoration:underline;">Section&#160;8.1.2(b)</font>);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M273"></a><a name="_Ref443311689"></a><a name="_Ref443049160"></a><a name="_Ref443049500"></a><font style="text-decoration:underline;">Joint Governance</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;If, and for so long as,&#160;Mitsui&#8217;s Pro Rata Share is equal to more than forty-five percent (45%), the Company shall be deemed to become a 50/50 joint venture between the BioAmber Parties and Mitsui from a governance perspective.&nbsp;&nbsp;Accordingly, upon such event, all matters submitted to approval by the Shareholders shall require, and the Company shall not take any such action without, the prior written consent of each Shareholder, and BioAmber Lux shall no longer have the BioAmber Right to Approve with respect to any matters.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">25</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M274"></a><a name="_Ref244074337"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.1.5</font><font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Meetings</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The Boa</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">rd shall convene ordinary meetings of the Shareholders as required by Applicable Law and as set forth in the Company&#8217;s Charter Documents, and shall convene an extraordinary meeting of the Shareholders when requested by any Director (other than a Director n</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ominated by a Defaulting Shareholder).&nbsp;&nbsp;All Shareholders&#8217; meetings shall be conducted in accordance with the terms of this Agreement and the Company&#8217;s Charter Documents, and shall be presided over by the Chairman or, in his or her absence, any other Direct</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M274"></a><a name="_Ref244074337"></a>or elected to preside over the meeting by the then-attending Directors.&nbsp;&nbsp;</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">The Board shall prepare the agenda for each Shareholders&#8217; meeting and may provide a recommendation with respect to any business set forth on such agenda.&nbsp;&nbsp;The language for all Shareho</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">lders&#8217; meetings shall be English, and all minutes and other documents presented to Shareholders shall be prepared in English.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M275"></a><a name="_Ref251866296"></a>8.1.6<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Notice</font>.&nbsp;&nbsp;The Secretary shall give notice to the Shareholders (other than any Defaulting Shareholder) specifying the date and time for each Shareholders&#8217; meeting, accompanied by an agenda specifying the business of such meeting; <font style="font-style:italic;">provided</font>, that in the event the Secretary fails to timely provide such notice, the Director calling such meeting may provide such notice himself or herself.&nbsp;&nbsp;Not fewer than fourteen (14) days&#8217; prior written notice from the Secretary shall be given to all Shareholders (other than any Defaulting Shareholder); <font style="font-style:italic;">provided</font>, <font style="font-style:italic;">however</font>, that such notice period may be reduced with the written consent of all Shareholders entitled to vote at such meeting.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M276"></a><a name="_Ref244080217"></a>8.1.7<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Quorum</font>.&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Section 18.1.2</font>, at any Shareholders&#8217; meeting, presence of Shareholders holding at least seventy-five percent (75%) of the then issued and outstanding voting Shares shall constitute a quorum, subject to the following provisions of this <font style="text-decoration:underline;">Section 8.1.6</font>.&nbsp;&nbsp;If such a quorum is not present within one&#160;(1) hour from the time appointed for the Shareholders&#8217; meeting due to the absence of the duly authorized representative(s) of a Shareholder (the &#8220;<font style="font-weight:bold;font-style:italic;">Absent Shareholder</font>&#8221;), the meeting shall be postponed to such place and time as the Chairman shall decide, which shall be no earlier than fourteen (14) days after written notice of such postponed meeting has been given to all Shareholders.&nbsp;&nbsp;If, at such postponed meeting, such quorum is still not present due to the continuing absence of the Absent Shareholder, the Shareholders present at such postponed meeting shall be deemed a quorum and may transact the business for which the postponed meeting was originally convened (except with respect to any action that may only be approved in accordance with <font style="text-decoration:underline;">Section 8.1.2</font> or <font style="text-decoration:underline;">8.1.3</font>).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M277"></a>8.1.8<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Shareholders&#8217; Access</font>.&nbsp;&nbsp;Each Shareholder (through its designated representatives) other than a Defaulting Shareholder, which shall not have such right, shall be entitled to examine the Books and Records of the Company and shall have reasonable access, at all reasonable times and with prior written notice, to any and all properties and assets of the Company (subject to standard security measures applicable at any such property).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M278"></a>8.1.9<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">No Authority of Shareholders to Act on Behalf of Company</font>.&nbsp;&nbsp;No Shareholder shall act as an agent of the Company or have any authority to act for or to bind the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">26</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M279"></a><a name="_Toc444101311"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.2</font><font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Board</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M280"></a><a name="_Ref161806172"></a><a name="_DV_M281"></a>8.2.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Authority of the Board</font>.&nbsp;&nbsp;Subject to the provisions of this Agreement (including <font style="text-decoration:underline;">Sections 8.1.2</font> and <font style="text-decoration:underline;">8.1.3</font>), the Company&#8217;s Charter Documents and Applicable Law, the management of the Company shall be exercised by the Board, which shall have full power and discretion to take all actions that it considers necessary or desira<a name="_DV_M281"></a>ble in connection with the management of the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M282"></a>8.2.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Number and Composition</font>.&nbsp;&nbsp;The Board shall consist of six&#160;(6) Directors.&nbsp;&nbsp;BioAmber Lux shall have the right to nominate three&#160;(3) Directors and Mitsui shall have the right to nominate three&#160;(3) Directors.&nbsp;&nbsp;Each Shareholder shall vote its Shares for the appointment of any Director(s) nominated by the other Shareholder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M283"></a><a name="_Ref301980559"></a>8.2.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Chairman</font>.&nbsp;&nbsp;The Chairman shall be selected by a majority vote of the Directors then in office.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M284"></a><a name="_Ref301984560"></a><a name="_DV_M285"></a><a name="_Ref243822760"></a><a name="_DV_M286"></a><a name="_DV_M287"></a>8.2.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Removal and Replacement of Directors</font><a name="_DV_M285"></a><a name="_Ref243822760"></a>.&nbsp;&nbsp;A Director shall be removed from the Board, with or without cause, only upon the affirmative vote of the Shareholders in accordance with this <font style="text-decoration:underline;">Section 8.2.4</font>.&nbsp;&nbsp;Each Shareholder shall vote its Shares for the removal of a Director upon the written request of the Shar<a name="_DV_M286"></a>eholder that nominated such Director.&nbsp;&nbsp;Otherwise, no Shareholder shall vote for the removal of any Director.&nbsp;&nbsp;In the event that any Director resigns or is removed in accordance with this <font style="text-decoration:underline;">Section 8.2.4</font>, the Shareholder that nominated such Director shall hav<a name="_DV_M287"></a>e the right to nominate such Director&#8217;s successor or replacement, and such successor or replacement Director shall be nominated and elected on or as soon as practicable after the date of such resignation or removal.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M288"></a>8.2.5<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Directors&#8217; Access</font>.&nbsp;&nbsp;Each Director (other than a Director nominated by a Defaulting Shareholder, who shall not have such right) shall be entitled to examine the Books and Records of the Company, shall have reasonable access, at all reasonable times and with prior written notice, to any and all properties and assets of the Company (subject to standard security measures applicable at any such property), and shall otherwise have full access to all the information pertaining to the Company, including its business and financial information (including access to hard-drives).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M289"></a>8.2.6<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Frequency and Location of Board Meetings; Deliberations</font>.&nbsp;&nbsp;Meetings of the Board shall take place at least once each calendar quarter.&nbsp;&nbsp;Meetings shall be held in a location approved by all of the Directors or, failing such approval, at the principal place of business of the Company.&nbsp;&nbsp;All deliberations at Board meetings shall be held, and all resolutions shall be passed, in English.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M290"></a>8.2.7<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Notice</font>.&nbsp;&nbsp;A Board meeting may be called by any Director (other than any Director nominated by a Defaulting Shareholder), by written notice to the Secretary specifying the date, time and agenda for such meeting.&nbsp;&nbsp;The Secretary shall, upon receipt of any such notice, provide a copy of such notice to all Directors (other than any Director(s) nominated by a Defaulting Shareholder), accompanied by an agenda specifying the business of such meeting and copies of </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">27</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">all documents and other information materially relevant for such meeting; </font><font style="font-style:italic;">provided</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, that in the event the Secretary fails to timely provide such notice, the D</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">irector calling such meeting may provide such notice himself or herself.&nbsp;&nbsp;Not less than fourteen (14) days&#8217; prior notice, delivered in writing, shall be given to all Directors (other than any Director(s) nominated by a Defaulting Shareholder); </font><font style="font-style:italic;">provided, ho</font><font style="font-style:italic;">wever</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, that such notice period (i) shall not apply in the case of an adjourned meeting pursuant to </font><font style="text-decoration:underline;">Section 8.2.8</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> and (ii) may be reduced with the written consent of all of the Directors entitled to vote at such meeting.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M291"></a><a name="_Ref301982354"></a><a name="_Ref301983858"></a><a name="_DV_M292"></a>8.2.8<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Quorum</font><a name="_DV_M292"></a>.&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Section 18.1.2</font>, attendance of at least one&#160;(1) Director nominated by BioAmber Lux and one&#160;(1) Director nominated by Mitsui shall be required to constitute a quorum for any meeting of the Board, subject to the following provisions of this <font style="text-decoration:underline;">Section 8.2.8</font>.&nbsp;&nbsp;If such a quorum is not present within one&#160;(1) hour from the time specified for any duly called meeting, the meeting shall be postponed to such place and time as a majority of the then-attending Directors shall decide or, in the absence of such decision, as the Chairman shall decide, which shall be no earlier than seven&#160;(7) days after written notice of such postponed meeting has been given to all Directors, and, at any such postponed meeting, a quorum shall consist of, at least, a majority of the Directors.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M293"></a>8.2.9<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Voting</font>.&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Section 18.1.2</font>, at any Board meeting, each Director may exercise one&#160;(1) vote, and the adoption of any resolution of the Board shall require the affirmative vote of a simple majority of the Directors present at a duly constituted meeting of the Board (it being understood that if a matter submitted to the Board fails to obtain such majority approval, such matter shall not be adopted or otherwise implemented by the Company; <font style="font-style:italic;">provided</font>, that in the event the Board fails to obtain the required majority approval with respect to any of the actions set forth in <font style="text-decoration:underline;">Section&#160;8.1.2(a)</font>, <font style="text-decoration:underline;">8.1.2(b)</font> or <font style="text-decoration:underline;">8.1.2(c)</font>, then any Director may submit such proposed action to the Shareholders for their approval thereof in accordance with <font style="text-decoration:underline;">Section&#160;8.1.2</font>).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M294"></a>8.2.10<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Means of Participation</font>.&nbsp;&nbsp;To the extent permitted by Applicable Law, (i)&#160;Directors may participate in a Board meeting by telephone or video conference, <font style="font-style:italic;">provided </font>that each Director can hear and be heard by all other Directors throughout the meeting, and (ii)&#160;participation by such means shall constitute presence for purposes of the quorum provisions of <font style="text-decoration:underline;">Section 8.2.8</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M295"></a>8.2.11<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Action by Written Consent</font>.&nbsp;&nbsp;To the extent permitted by Applicable Law, any action that may be taken by the Directors at a duly constituted meeting may be taken by a written resolution (in one or more counterparts) signed by all the Directors entitled to vote at such meeting.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M296"></a><a name="_Ref301986613"></a><font style="text-decoration:underline;">BioAmber IP</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;In the event that BioAmber or any Affiliate thereof intends to execute any transaction or arrangement that would affect the Company&#8217;s BSA production, including any transaction or arrangement involving (a)&#160;the assignment, transfer or exclusive license of any intellectual property that is the subject of the licenses granted by BioAmber and/or BioAmber Lux to the Company or (b)&#160;the grant of any security interest or other encumbrance with respect to such intellectual property, then prior to entering into such transaction or arrangement BioAmber shall report the proposed terms and conditions thereof to the Board.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">28</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.2.13</font><font style="margin-left:144pt;"></font><font style="text-decoration:underline;">No Compensation; Expenses</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The Directors shall not receive any compensation from the Company for their service as Director</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">s.&nbsp;&nbsp;The Company shall reimburse the Directors for their reasonable out-of-pocket expenses in connection with serving as Directors, including any travel, lodging and other costs of attendance at meetings of the Board.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M297"></a><a name="_Ref243823334"></a><a name="_Ref301987536"></a><a name="_Ref302551351"></a><a name="_DV_M298"></a><a name="_DV_M299"></a>8.2.14<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Indemnification of Directors; Director Insurance</font><a name="_DV_M298"></a>.&nbsp;&nbsp;The Company shall indemnify and hold harmless each of the Directors, in accordance with the terms and subject to the conditions set forth in an indemnification agreement, which the Company and the Shareholders shall negotiate in good faith to execute as promptly as practicable after the date hereof (the &#8220;<font style="font-weight:bold;font-style:italic;">Indemnification Agreement</font><a name="_DV_M299"></a>&#8221;).&nbsp;&nbsp;The Company has purchased, and shall maintain at all times, Director insurance (with the amount of the coverage determined by the Board) for all Directors, retroactive to the date of formation of the Company and payable to the Company as beneficiary.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M300"></a><a name="_Toc444101312"></a>8.3<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Officers</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443732537"></a>8.3.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">General</font>.&nbsp;&nbsp;The Company shall have such officers as the Board may appoint from time to time, and all such officers shall be subject to removal at any time at the discretion of the Board.&nbsp;&nbsp;Such officers shall have such duties as may be delegated thereto by the Board and as are customarily possessed by officers in similar positions in the relevant jurisdiction (except as such duties may be restricted by the Board), subject to the provisions of this Agreement, the Company&#8217;s Charter Documents and Applicable Law.&nbsp;&nbsp;Notwithstanding the foregoing, the Shareholders agree that Mitsui shall have the right to appoint one officer of the Company by delivering written notice thereof to BioAmber and the Company, which officer will be engaged in administrative, financial and/or other areas as BioAmber and Mitsui shall mutually agree in good faith.&nbsp;&nbsp;The position, title and other terms and conditions for such officer shall also be agreed by BioAmber and Mitsui in good faith.&nbsp;&nbsp;The Shareholders further agree that Mitsui shall have the right, from time to time, to replace such officer with another individual designated by it by delivering written notice thereof to BioAmber and the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443048120"></a>8.3.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">CCO</font>.&nbsp;&nbsp;In addition to, and notwithstanding, the provisions of <font style="text-decoration:underline;">Section&#160;8.3.1</font>, Mitsui shall have the right to nominate, and thereafter replace, the CCO, who shall be appointed to such position by the Company and report to the President.&nbsp;&nbsp;The President shall delegate to the CCO the responsibility for<font style="font-weight:bold;font-style:italic;"> </font>the Opportunity Assessments, based on processes and criteria established by the President, subject to <font style="text-decoration:underline;">Section&#160;9.1</font> and the corporate governance rules and policies of the Company approved by the Board.&nbsp;&nbsp;The CCO shall coordinate the commercial efforts of BioAmber, Mitsui and Vinmar with respect to the joint venture in accordance with the Company&#8217;s Marketing Policy and its Sales and Marketing Principles.&#160; The CCO shall also be responsible for the coordination of the sales activities, tracking progress and overseeing reporting of the Company, and shall chair the &#8220;Marketing Committee&#8221; as defined in the Vinmar TOP.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.3.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Officers&#8217; Access</font>.&nbsp;&nbsp;Each officer of the Company shall have full access to all the information pertaining to the Company, including its business and financial information (including access to hard-drives).</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">29</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M301"></a><a name="_Toc444101313"></a><font style="text-decoration:underline;">Plant Manager</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The day-to-day operations of the Initial Plant shall be responsibility of the Plant Manager, who, subject to <font style="text-decoration:underline;">Section 8.1.2</font>, shall be nominated by BioAmber Lux.&nbsp;&nbsp;The Plant Manager shall report directly to the Board.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M302"></a><a name="_Toc444101314"></a><a name="_Ref375228979"></a><font style="text-decoration:underline;">Secondment</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Mitsui shall have the right, but not the obligation, to second and appoint a representative to the Company, and to remove any such appointed representative, in Mitsui&#8217;s discretion.&nbsp;&nbsp;Any such secondment shall be on such terms, including as to cost to be charged to the Company, to be agreed among Mitsui, BioAmber and the Company (subject to <font style="text-decoration:underline;">Section 8.1.3</font>).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101315"></a><a name="_Ref375228992"></a><font style="text-decoration:underline;">Commissioning &amp; Start-Up Team</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Mitsui shall also have the right, but not the obligation, to appoint a representative to serve as a member of the Company&#8217;s Commissioning &amp; Start-Up Team, and to remove any such appointed representative, in Mitsui&#8217;s discretion.&nbsp;&nbsp;Any such appointment shall be on such terms, including as to cost to be charged to the Company, to be agreed among Mitsui, BioAmber and the Company (subject to <font style="text-decoration:underline;">Section 8.1.3</font>).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101316"></a><font style="text-decoration:underline;">EPC Matters</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Any representative to the Company appointed by Mitsui pursuant to <font style="text-decoration:underline;">Section&#160;8.5</font> or <font style="text-decoration:underline;">8.6</font> shall be entitled to attend and participate in all meetings of the Company&#8217;s project management team(s) concerning engineering, procurement and/or construction matters, including any meetings with EPC Firms, and the Company shall otherwise maintain such representatives reasonably informed, and provide them with any information they reasonably request, regarding such matters.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101317"></a><font style="text-decoration:underline;">Annual Budget</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The annual budget of the Company approved pursuant to this Agreement shall be executed in accordance with the corporate governance rules and policies of the Company, including any relevant delegation of authority approved by the Board.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M303"></a><a name="_Toc444101318"></a><font style="text-transform:none;">OTHER OPERATIONAL MATTERS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M304"></a><a name="_Toc444101319"></a><a name="_Ref443051803"></a><font style="text-decoration:underline;">Opportunity Assessments</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;In the event that the net back price for a sale opportunity of the Company is lower than the &#8220;Marketing Floor Price&#8221; (as defined and approved by the Board) but not lower than the &#8220;Plant Floor Price&#8221; (as defined and approved by the Board), the Company shall assess such sales opportunity, including whether and how to execute the sale with the customer/distributor as proposed in such opportunity (the &#8220;<font style="font-weight:bold;font-style:italic;">Opportunity Assessment</font>&#8221;), as further provided herein.&nbsp;&nbsp;The CCO shall be authorized to formally evaluate the Opportunity Assessment and make a final decision on its approval and the conditions associated therewith (if any), and whether and how to execute the sale of products as contemplated by the Opportunity Assessment; <font style="font-style:italic;">provided</font>, that in the event the CCO<font style="font-family:MS Mincho;"> </font>declines to execute such sale of products, the President may overturn the CCO&#8217;s decision and make a final decision to execute such sale of products, if (i)&#160;the President believes that it is in the best interest of the Company to execute such sale of products as contemplated by the Opportunity Assessment, after the President carefully reviews the CCO&#8217;s decision, and (ii)&#160;the Minimum Volume exceeds 100 metric ton or such other volume that the Board may separately determine from time to time.&nbsp;&nbsp;The application for approval of an Opportunity Assessment and the approval thereof by the CCO or President, as the case may be, shall include the minimum volume of products that the Company shall offer per Contract, agreement or other </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">30</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">document of legally binding nature</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&nbsp;&nbsp;to the</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> relevant customer/distributor if the Opportunity Assessment is approved by the Company, below which the Company shall not be authorized to execute sale of products as proposed in the Opportunity Assessment (&#8220;</font><font style="font-weight:bold;font-style:italic;">Minimum Volume</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221;).</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&nbsp;&nbsp;For clarity, the Marketing </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Floor Price and the Plant Floor Price shall not constitute part of the Company&#8217;s annual budget over which BioAmber Lux would have the BioAmber Right to Approve pursuant to </font><font style="text-decoration:underline;">Section&#160;</font><font style="text-decoration:underline;">8.1.2</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101320"></a><font style="text-decoration:underline;">Dividend/Distribution Policy</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M305"></a><a name="_DV_M306"></a><a name="_DV_M305"></a>.&nbsp;&nbsp;At least once every Financial Year, all funds of the Company then available for distribution under Applicable Law, after deducting only any amounts that are required to (i) meet then-legally binding commitments and reasonably foreseeable contingencies and (ii) maintain or expand the Initial Plant in accordance with the then-approved annual budget, shall be distributed to the Shareholders as dividends in accordance with their respective <a name="_DV_M306"></a>Pro Rata Shares or in any other matter unanimously agreed by the Shareholders.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101322"></a>9.3<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Books and Records; Financial Statements</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M307"></a><a name="_DV_M308"></a><a name="_Ref301990894"></a><a name="_Ref248578795"></a>9.3.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Books and Records</font>.&nbsp;&nbsp;The Company shall keep and maintain Financial Statements, books, records and other accounts, in reasonable detail (collectively, the &#8220;<font style="font-weight:bold;font-style:italic;">Books and Records</font>&#8221;), which accurately and fairly reflect its transactions and dispositions of assets, governance and other operational matters.&nbsp;&nbsp;The Company shall further keep and maintain the Books and Records at all times in compliance with all record keeping and reporting requirements required by Applicable Law.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M309"></a><a name="_Ref248576522"></a>9.3.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Financial Statements</font>.&nbsp;&nbsp;The Financial Statements shall be maintained in Dollars and in accordance with IFRS and shall be audited annually by Deloitte &amp; Touche or such other of the &#8220;Big Four&#8221; international accounting firms as is selected by the Board.&nbsp;&nbsp;The Company shall devise and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed and access to assets is permitted only in accordance with management&#8217;s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of periodic financial statements and to maintain accountability for assets; and (iii) actual assets and recorded assets (and related accounting values) are compared at reasonable intervals and appropriate action is taken to address any inconsistencies.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M310"></a><a name="_Toc444101323"></a>9.4<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Information Rights</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M311"></a><a name="_Ref369630732"></a>9.4.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Financial Statements</font>.&nbsp;&nbsp;The Company shall provide to each Shareholder (i)&#160;within ninety&#160;(90) days after the end of each Financial Year, the annual audited Financial Statements for such Financial Year; (ii) within thirty&#160;(30) days after the end of each quarter of each Financial Year, quarterly unaudited Financial Statements for such quarter; and (iii) within ten&#160;(10) days after the end of each month of each Financial Year, monthly trial balances of the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">9.4.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Operations Reports.</font>&nbsp;&nbsp;The Company shall provide, and BioAmber shall cause the Company to provide, to Mitsui, within fifteen (15) days after the end of each calendar month, monthly written reports setting forth in reasonable detail the production, operation and performance of the Initial Plant, including (i)&#160;capital expenditures by item (regardless of whether </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">31</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">capitalized or expensed) for the </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">preceding monthly period; (ii)&#160;raw material and utilities consumption by item for the preceding monthly period; (iii) key performance indicators of fermentation per batch, including titer, yield and productivity for the preceding monthly period; (iv)&#160;key p</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">erformance indicators of the downstream process for the preceding monthly period; (v)&#160;emission and effluents</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">in the preceding monthly period; (vi)&#160;volume of finished products produced by specification in the preceding monthly period; (vii)&#160;volume of co-pro</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ducts produced</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">in the preceding monthly period; (viii)&#160;volume of products and co-products sold and inventory stored by grade</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">in the preceding monthly period; (ix)&#160;variable cost per kilogram of product and its breakdown by raw material, utilities and others</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> by item for the preceding monthly period; (x)&#160;annual cash requirements of the Company on a monthly basis; (xi)&#160;cash requirements of the Company on a weekly basis for at least the upcoming three (3) months; (xii) any deviation from the annual budget, an ex</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">planation of such deviation and any change in the forecast of the Company&#8217;s performance; and (xiii)&#160;such additional information regarding the Company&#8217;s operations as Mitsui may reasonably request.&nbsp;&nbsp;The Company shall provide Mitsui with supplemental informa</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">tion, explanation and documents that reasonably satisfies request for clarification or question from Mitsui.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M312"></a>9.4.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Construction Reports</font>.&nbsp;&nbsp;During the period prior to the Operational Date, the Company shall provide to each Shareholder monthly written reports setting forth in reasonable detail the progress of the construction of the Initial Plant, including (i) any material difficulties or delays encountered and all measures being taken (or considered) to address such difficulties or delays and (ii) the costs associated with the construction to date and how such costs compare to those agreed to by the Parties.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M313"></a>9.4.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Other Information</font>.&nbsp;&nbsp;The Company shall prepare and provide, at its expense, any additional information or materials that may be reasonably requested by any Shareholder to enable it to comply with its internal policies regarding accounting and disclosure requirements as well as the requirements of any applicable securities regulatory authority, including any stock exchange on which the securities of such Shareholder (or any Affiliate thereof) are traded.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M314"></a><a name="_Toc444101324"></a><font style="text-decoration:underline;">Insurance</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The Company shall obtain and maintain, at its cost, adequate insurance in respect of its assets, properties and operations as determined by the Board, and the other parties shall reasonably cooperate, if and to the extent requested by the Company, to assist the Company in obtaining such insurance.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M315"></a><a name="_Toc444101325"></a><a name="_DV_M316"></a><a name="_DV_M316"></a>ENCUMBRANCE OR TRANSFER OF SHARES</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M317"></a><a name="_Toc444101326"></a><font style="text-decoration:underline;">Proxies and Voting Trusts</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Each of the BioAmber Parties and Mitsui agrees not to grant to any third party any proxy or enter into, or become bound by, any voting trust with respect to its Shares, or enter into arrangements of any kind with any Person with respect to its Shares, in any such case in a manner that is inconsistent with this Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">32</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M318"></a><a name="_Toc444101327"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">10.2</font><font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Restrictions on Transfer</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M319"></a><a name="_Ref164403185"></a><a name="_DV_M320"></a><a name="_Ref164416175"></a>10.2.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">No Transfers or Encumbrances</font>.&nbsp;&nbsp;Except with the prior written consent of the other Shareholder or as otherwise expressly permitted by this Agreement, no Shareholder shall, directly or indirectly, (i) sell, assign, donate or otherwise transfer or dispose of, in any way or manner whatsoever, whether voluntarily or involuntarily, by operation of law or otherwise (collectively, &#8220;<font style="font-weight:bold;font-style:italic;">Transfer</font>&#8221;), or (ii) pledge, mortgage, hypothecate or otherwise encumber, in any way or manner whatsoever, whether voluntarily or involuntarily, by operation of law or otherwise (collectively, as the context may require, &#8220;<font style="font-weight:bold;font-style:italic;">Encumber</font>&#8221; or &#8220;<font style="font-weight:bold;font-style:italic;">Encumbrance</font><a name="_DV_M320"></a><a name="_Ref164416175"></a>&#8221;), the legal or beneficial ownership of, or economic benefits pertaining to, any of its Shares.&nbsp;&nbsp;Each certificate for any Shares now held or hereafter acquired by any Shareholder shall, for as long as this Agreement is effective, bear an appropriate legend regarding the Transfer restrictions applicable in respect of such Shares.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M321"></a>10.2.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Invalid Transfers/Encumbrances</font>.&nbsp;&nbsp;Any purported Transfer or Encumbrance of Shares in violation of this Agreement shall be null and void and shall not operate to Transfer or Encumber any right, title or interest to or in favor of the purported transferee, and the Company shall not recognize or give effect to any such purported Transfer or Encumbrance.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M322"></a><a name="_Ref301995206"></a><a name="_DV_M323"></a>10.2.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Permitted Transfers</font>.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, each Shareholder may Transfer all or a portion of its Shares to a direct or indirect majority owned subsidiary of such Shareholder (or, in the case of BioAmber Lux, to BioAmber or another direct or indirect majority owned subsidiary of BioAmber) (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Permitted Transferee</font>&#8221;); <font style="font-style:italic;">provided</font>, that (a) such Shareholder shall pay all costs, including any taxes and fees, associated with such Transfer, and (b) as conditions precedent to the effectiveness of such Transfer, (i) any Permitted Transferee to whom Shares are transferred shall agree to be bound by the terms of this Agreement by entering into a Joinder Agreement with the Company, (ii) BioAmber or Mitsui, as applicable, shall guarantee all obligations of such Permitted Transferee under this Agreement pursuant to a guarantee agreement in form and substance reasonably acceptable to BioAmber or Mitsui, as applicable, (iii) any Consents required in connection with such Transfer shall have been obtained, (iv) such Shareholder shall cause such Permitted Transferee to re-transfer all transferred Shares to such Shareholder (or another Permitted Transferee thereof) in accordance with the terms hereof prior to it ceasing to be a direct or indirect majority owned subsidiary of such Shareholder (or, in the case of BioAmber Lux, of BioAmber) and (v) notwithstanding such Transfer, the transferring Shareholder shall remain solely responsible under the Ancillary Agreements to which it is a party.&nbsp;&nbsp;Any Permitted Transferee to whom Shares are transferred in accordance with this Agreement shall be entitled to the rights and benefits of the transferring Shareholder under this Agreement as if it were an original party hereto<a name="_DV_M323"></a>, and any reference herein to a particular Shareholder shall be deemed to be a reference to such Shareholder and its Permitted Transferees.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M324"></a><a name="_Ref164404163"></a><a name="_Toc444101328"></a>RIGHT OF FIRST OFFER; RIGHT OF FIRST REFUSAL; DRAG-ALONG; CO-SALE</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M325"></a><a name="_Ref174545663"></a><a name="_Toc444101329"></a>11.1<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Right of First Offer</font>.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">33</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M326"></a><a name="_Ref301996588"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">11.1.1</font><font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Right of First Offer</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;A S</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">hareholder (a &#8220;</font><font style="font-weight:bold;font-style:italic;">Transferring Shareholder</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221;) may propose to Transfer all (but not less than all) of its Shares (the &#8220;</font><font style="font-weight:bold;font-style:italic;">Offered Shares</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221;) to any Person who is not a Permitted Transferee; </font><font style="font-style:italic;">provided</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, that the other Shareholder (the &#8220;</font><font style="font-weight:bold;font-style:italic;">Offering Shareholder</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221;) shall have</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> a right of first offer in respect of the Offered Shares in accordance with the provisions of this </font><font style="text-decoration:underline;">Section 11.1</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M327"></a><a name="_Ref302489892"></a>11.1.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Offer Notice</font>.&nbsp;&nbsp;The Transferring Shareholder shall give prior written notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Offer Notice</font>&#8221;) to the Offering Shareholder of the Transferring Shareholder&#8217;s desire to Transfer the Offered Shares to a Person who is not a Permitted Transferee.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M328"></a><a name="_Ref301998304"></a><a name="_Ref174545922"></a><a name="_Ref302028311"></a><a name="_DV_M329"></a><a name="_DV_M330"></a>11.1.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Transfer Negotiation Period; Closing</font>.&nbsp;&nbsp;If within thirty&#160;(30) days after the date on which it received the Offer Notice, the Offering Shareholder provides to the Transferring Shareholder written notice of its interest in purchasing the Offered Shares (a &#8220;<font style="font-weight:bold;font-style:italic;">ROFO Exercise Notice</font>&#8221;), for a period of sixty&#160;(60) days after the date on which the Offering Shareholder received the Offer Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Transfer Negotiation Period</font>&#8221;), the Transferring Shareholder and the Offering Shareholder shall negotiate in good faith with the objective of mutually agreeing on the price and other terms and conditions for the Offering Shareholder&#8217;s purchase of the Offered Shares (collectively, the &#8220;<font style="font-weight:bold;font-style:italic;">Transfer Terms</font>&#8221;).&nbsp;&nbsp;During the Transfer Negotiation Period, the Transferring Shareholder shall not solicit any offer from, discuss, engage in negotiations or enter into any Contract with, any Person (other than the Offering Shareholder) with respec<a name="_DV_M329"></a><a name="_DV_M330"></a>t to the Offered Shares.&nbsp;&nbsp;If the Transferring Shareholder and the Offering Shareholder reach an agreement on the Transfer Terms, the closing of such Transfer shall occur, subject to obtaining any required Consents, within thirty&#160;(30) days after the date of such agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M331"></a><a name="_Ref174546506"></a>11.1.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Transfer to Third Parties</font>.&nbsp;&nbsp;If (x) the Offering Shareholder fails to provide a ROFO Exercise Notice within the period therefor set forth in <font style="text-decoration:underline;">Section 11.1.3</font> or (y) the Transferring Shareholder and the Offering Shareholder are unable to reach an agreement on the Transfer Terms within the Transfer Negotiation Period, the Transferring Shareholder shall be entitled, subject to, if the Offering Shareholder is Mitsui (or its Permitted Transferee), <font style="text-decoration:underline;">Sections&#160;11.2</font> and&#160;<font style="text-decoration:underline;">11.4</font>, to offer and Transfer the Offered Shares, within a period of ninety&#160;(90) days after the expiration of the Transfer Negotiation Period, to any other Person for a price and on other terms no more favorable to such Person than the price and other terms last proposed by the Transferring Shareholder to the Offering Shareholder during their negotiation as contemplated by <font style="text-decoration:underline;">Section 11.1.3</font> (or, absent such proposal, the price and other terms last proposed by the Offering Shareholder to the Transferring Shareholder during such negotiation) (the &#8220;<font style="font-weight:bold;font-style:italic;">Offering Shareholder Terms</font>&#8221;), except in the event referred to in clause (x) above of this <font style="text-decoration:underline;">Section 11.1.4</font>, in which case the Transferring Shareholder may so offer and Transfer the Shares to such Person at any price and on any other terms as the Transferring Shareholder and such Person may agree.&nbsp;&nbsp;If such Transfer is not consummated within such ninety&#160;(90) day period, the Transferring Shareholder shall be required to comply again with the procedures set forth in this <font style="text-decoration:underline;">Section 11.1</font> as if it had never given an Offer Notice.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">11.1.5<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Change of Control</font>.&nbsp;&nbsp;For the avoidance of doubt, the provisions of this <font style="text-decoration:underline;">Section 11.1</font> shall not apply in respect of a Change of Control of BioAmber or Mitsui (subject to the Co-Sale Right set forth in <font style="text-decoration:underline;">Section 11.4</font>).</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">34</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M332"></a><a name="_Ref443054848"></a><a name="_Ref443055499"></a><a name="_Toc444101330"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">11.2</font><font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Right</font><font style="text-decoration:underline;"> of First Refusal</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref443299197"></a><a name="_Ref443301176"></a>11.2.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Right of First Refusal</font>.&nbsp;&nbsp;Without prejudice, and in addition, to Mitsui&#8217;s right of first offer as an Offering Shareholder under <font style="text-decoration:underline;">Section 11.1</font> and the Co-Sale Right under <font style="text-decoration:underline;">Section&#160;11.4</font>, in the event that a BioAmber Party (or its Permitted Transferee) (the &#8220;<font style="font-weight:bold;font-style:italic;">Transferring BioAmber Party</font>&#8221;) intends to Transfer Shares to any Person who is not a Permitted Transferee, then before making or agreeing to make (except that such agreement may be made if subject to Mitsui&#8217;s right of first refusal hereunder) such Transfer, the Transferring BioAmber Party shall give written notice to Mitsui, including the name and address of the proposed transferee, the number of Shares proposed to be transferred, the price per Share and all other material terms and conditions of the proposed Transfer (such notice, which shall include a copy of any written offer or definitive agreement (which shall be subject to Mitsui&#8217;s right of first refusal hereunder) in respect of such proposed Share Transfer, the &#8220;<font style="font-weight:bold;font-style:italic;">First Refusal Notice</font>&#8221;).&nbsp;&nbsp;The First Refusal Notice will constitute an offer by the Transferring BioAmber Party to sell Shares to Mitsui, upon the terms and in the quantity set forth in the First Refusal Notice (including the terms of any written offer or definitive agreement included therewith).&nbsp;&nbsp; If Mitsui accepts such offer by delivering written notice to BioAmber within sixty (60) days of its receipt of the First Refusal Notice, the closing of such Transfer shall occur, subject to obtaining any required Consents, within thirty&#160;(30) days after the date of Mitsui&#8217;s acceptance.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">11.2.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Transfer to Third Parties</font>.&nbsp;&nbsp;If Mitsui does not accept such offer within sixty (60) days of its receipt of the First Refusal Notice, the Transferring BioAmber Party may Transfer Shares to the proposed transferee pursuant to the terms and in the quantity identified in the First Refusal Notice.&nbsp;&nbsp;Such Transfer shall take place within sixty (60) days of the end of the sixty (60) day period mentioned above; <font style="font-style:italic;">provided</font> that, if the Transfer of Shares does not take place during such sixty (60) day period, the Transferring BioAmber Party shall not be entitled to Transfer the Shares to the proposed transferee unless the Transferring BioAmber Party again offers the Shares to Mitsui in accordance with the procedure set forth herein.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">11.2.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Change of Control; Transfer of All Shares</font>.&nbsp;&nbsp;For the avoidance of doubt, (a)&#160;the provisions of this <font style="text-decoration:underline;">Section&#160;11.2</font> shall not apply in respect of a Change of Control of BioAmber, and (b)&#160;nothing herein shall be deemed to amend or otherwise modify the provision in <font style="text-decoration:underline;">Section&#160;11.1.1</font> to the effect that a Shareholder may only Transfer all (but not less than all) of its Shares to any Person who is not a Permitted Transferee.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M333"></a><a name="_Ref174549939"></a><a name="_Toc444101331"></a>11.3<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">BioAmber Drag-Along Right</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M334"></a><a name="_Ref174548765"></a>11.3.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Drag-Along Right</font>.&nbsp;&nbsp;In the event that (i) any of the BioAmber Parties undergoes a Change of Control or (ii) BioAmber Lux (or any Permitted Transferee thereof) Transfers its Shares to a Person other than a Permitted Transferee pursuant to <font style="text-decoration:underline;">Section 11.1</font> or <font style="text-decoration:underline;">11.2</font> (each of the events described in clauses (i) and (ii) above, a &#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Triggering Event</font>&#8221;), BioAmber shall have the right (the &#8220;<font style="font-weight:bold;font-style:italic;">Drag-Along Right</font>&#8221;) to require Mitsui to sell all (but not less than all) of the Shares held by Mitsui (and any Permitted Transferee thereof) to the acquirer of the applicable assets/interests (the &#8220;<font style="font-weight:bold;font-style:italic;">Third Party Acquirer</font>&#8221;) at a purchase price in cash equal to two hundred percent (200%) of the aggregate amount of Mitsui&#8217;s equity contributions to the Company </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">35</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">as of the closing date of such purchase; </font><font style="font-style:italic;">provided</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, that the Drag-Along Right shall expire and no longer apply upon and after the earlier of (i) the date on which BioAmber completes an IPO and (ii) the Op</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">erational Date (such earlier date, the &#8220;</font><font style="font-weight:bold;font-style:italic;">Drag-Along</font><font style="font-style:italic;"> </font><font style="font-weight:bold;font-style:italic;">Expiration Date</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M335"></a>11.3.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Exercise of Drag-Along Right</font>.&nbsp;&nbsp;In order to exercise its Drag-Along Right, BioAmber shall, at least sixty&#160;(60) days prior to the closing or consummation of the applicable BioAmber Triggering Event, provide written notice to Mitsui of its exercise of the Drag-Along Right (in addition to the BioAmber Triggering Event Notice referred to below).&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Section&#160;11.5</font>, the closing of the purchase by the Third Party Acquirer of Mitsui&#8217;s Shares pursuant to BioAmber&#8217;s exercise of the Drag-Along Right (including the payment in full of the applicable purchase price to Mitsui) shall occur, subject to obtaining any required Consents, simultaneously with the closing or consummation of the applicable BioAmber Triggering Event.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M336"></a><a name="_Ref174546149"></a><a name="_Toc444101332"></a>11.4<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Mitsui Co-Sale Right</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M337"></a><a name="_Ref302491306"></a><a name="_DV_M338"></a>11.4.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BioAmber Triggering Event Notice</font>.&nbsp;&nbsp;BioAmber shall provide to Mitsui written notice of any BioAmber Triggering Event at least sixty&#160;(60) days prior to the closing or consummation of such BioAmber Triggering Event (the &#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Triggering Event Notice</font>&#8221;).&nbsp;&nbsp;The BioAmber Triggering Event Notice shall set forth a description of the material terms of the BioAmber Triggering<a name="_DV_M338"></a> Event to which it relates, including the nature of the transaction, purchase price, expected closing date and other relevant terms and conditions.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M339"></a><a name="_Ref302491564"></a>11.4.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Co-Sale Right</font>.&nbsp;&nbsp;Mitsui shall have the right (the &#8220;<font style="font-weight:bold;font-style:italic;">Co-Sale Right</font>&#8221;), by providing written notice to BioAmber within thirty&#160;(30) days after its receipt of the BioAmber Triggering Event Notice, to require the applicable Third Party Acquirer (or, at Mitsui&#8217;s option, BioAmber) to purchase all (but not less than all) of the Shares held by Mitsui (and any Permitted Transferee thereof), simultaneously with the closing or consummation of the applicable BioAmber Triggering Event, at a purchase price in cash equal to:</p>
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:12.31%;text-indent:10.31%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M340"></a>(x)<font style="margin-left:144pt;"></font><font style="margin-left:0pt;">if the BioAmber Triggering Event occurs prior to the Drag-Along Expiration Date, one hundred fifty </font>percent (150%) of the aggregate amount of Mitsui&#8217;s equity contributions to the Company as of the closing date of such purchase; or</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:12.5%;text-indent:10.58%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M341"></a>(y)<font style="margin-left:144pt;">if the BioAmber Triggering Event occurs on or after the Drag-Along Expiration Date, (A) the Book Value of such Shares on </font>the date Mitsui delivered such notice to BioAmber (if such BioAmber Triggering Event consists of the event referred to in clause (i) of the definition of BioAmber Triggering Event) or (B) the same purchase price per share at which BioAmber Lux (or any Permitted Transferee thereof) Transfers its Shares to a third-party (if such BioAmber Triggering Event consists of the event referred to in clause (ii) of the definition of BioAmber Triggering Event).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M342"></a><a name="_Ref302546867"></a>11.4.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Closing</font>.&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Section 11.5</font>, the closing of the purchase by such Third Party Acquirer (or BioAmber, if applicable) of the Shares held by Mitsui (and any Permitted </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">36</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Transferee thereof) pursuant to the exercise of the Co</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">-Sale Right (including the payment in full of the applicable purchase price to Mitsui or its applicable Permitted Transferee) shall occur, subject to obtaining any required Consents, simultaneously with the closing or consummation of the applicable BioAmbe</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">r Triggering Event.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M343"></a>11.4.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BioAmber Parties&#8217; Covenant</font>.&nbsp;&nbsp;If Mitsui exercises its Co-Sale Right, each of the BioAmber Parties (i) shall use its reasonable best efforts to cause the applicable Third Party Acquirer to purchase <font style="color:#000000;">the Shares held by Mitsui (and any Permitted Transferee thereof) in accordance with the provisions of this </font><font style="text-decoration:underline;color:#000000;">Section 11.4</font><font style="color:#000000;"> and (ii) shall </font>not, to the extent it is within its control, close or otherwise consummate the transaction constituting the BioAmber Triggering Event in respect of which Mitsui exercised its Co-Sale Right unless and until such Third Party Acquirer has purchased the Shares held by Mitsui (and any Permitted Transferee thereof) as provided herein.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M344"></a><a name="_Toc444101333"></a><a name="_Ref301999362"></a><a name="_Ref443474449"></a><font style="text-decoration:underline;">Terms of Mitsui Share Transfer</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M345"></a><a name="_DV_M345"></a>.&nbsp;&nbsp;The terms and conditions of any Contract pursuant to which Mitsui may Transfer its Shares pursuant to Section 11.3 or 11.4 shall be reasonably satisfactory to Mitsui, it being understood that neither Mitsui nor any Affiliate thereof shall be required under any such Contract to agree to any obligation or assume any liability (including making any representation or warranty) that is not specifically related to its ownership of Shares subject to such Transfer.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M346"></a><a name="_Ref174596001"></a><a name="_Toc444101334"></a><a name="_Ref180833445"></a>PUT/CALL OPTIONS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M347"></a><a name="_DV_M348"></a><a name="_Toc444101335"></a><a name="_Ref174595804"></a><a name="_Ref302025212"></a><font style="text-decoration:underline;">Put/Call Option</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M349"></a><a name="_DV_M349"></a>.&nbsp;&nbsp;In the event that Mitsui&#8217;s Pro Rata Share falls below ten percent (10%), (x) Mitsui shall have the right to sell to BioAmber Lux, and (y) BioAmber Lux shall have the right to purchase from Mitsui, all (but no less than all) of the Shares held by Mitsui (and any Permitted Transferee thereof) in either case at a purchase price in cash equal to one hundred percent (100%) of Mitsui&#8217;s aggregate equity contributions to the Company as of the closing date of such purchase.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101336"></a><a name="_Ref302025233"></a><a name="_Ref174595807"></a><a name="_Ref367798008"></a><font style="text-decoration:underline;">Mitsui Put Option During Construction of the Initial Plant</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M352"></a>.&nbsp;&nbsp;In the event that (a)&#160;BioAmber and Mitsui are unable to agree on the making of any payment by the Company in respect of the EPC Contract, which payment, together with all other payments made or agreed to be made by the Company under the EPC Contract, would exceed $140,000,000 and (b) the Company runs out of funds to pay for the continuing construction of the first phase of the Initial Plant (with an annual capacity of 30,000MT of BSA), Mitsui shall have the right to require that BioAmber Lux purchase all (but no less than all) of the Shares held by<font style="color:#000000;"> Mitsui (and any Permitted Transferee thereof) </font>at a purchase price in cash equal to one hundred percent (100%) <font style="color:#000000;">of Mitsui&#8217;s aggregate </font>equity contributions to the Company as of the closing date of such purchase; for the sake of clarity, the put option described in this <font style="text-decoration:underline;">Section 12.2</font> will not be applicable if one or both Shareholders and/or any third party(ies) have provided, or in the case of such third party(ies) have entered into a legally binding commitment to provide, and so provide before the Company runs out of funds to pay for the continuing construction of the Initial Plant, the Company with an Additional Contribution (which in the case of such third party(ies) shall solely be in the form of </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">37</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">equity) </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M352"></a>for an amount as to be able to complete the construction of the first phase of the Initial Plant (with an annual capacity of 30,000MT of BSA).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101337"></a><a name="_Ref368663975"></a><font style="text-decoration:underline;">Mitsui Put Option Resulting from the Occurrence of a Dissolution Event</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;During the period from and after the date of this Agreement until December 31, 2020, upon any occurrence of a Dissolution Event, <font style="color:#000000;">Mitsui shall have, in addition to its rights under </font><font style="text-decoration:underline;color:#000000;">Section&#160;</font>19.1<font style="color:#000000;">, the right to require that </font>BioAmber<font style="color:#000000;"> Lux purchase all (but no less than all) of the Shares held by Mitsui (and any Permitted Transferee thereof) </font>at a purchase price in cash equal to one hundred percent (100%) <font style="color:#000000;">of Mitsui&#8217;s aggregate </font>equity contributions to the Company as of the closing date of such purchase.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M350"></a><a name="_DV_M353"></a><a name="_Toc444101338"></a><a name="_Ref302028404"></a><a name="_Ref368655135"></a><font style="text-decoration:underline;">Additional Mitsui Put Option</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;During the period from and after the date of this Agreement until December 31, 2018, Mitsui shall have the right to require that BioAmber Lux purchase all (but no less than all) of the Shares held by Mitsui (and any Permitted Transferee thereof) at a purchase price in cash equal to fifty percent (50%) of Mitsui&#8217;s aggregate equity contributions to the Company as of the closing date of such purchase.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101339"></a><font style="text-decoration:underline;">Exercise of Options; Closing</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;To exercise its sale or purchase rights under <font style="text-decoration:underline;">Section&#160;12.1</font>, <font style="text-decoration:underline;">12.2,</font> <font style="text-decoration:underline;">12.3</font> or <font style="text-decoration:underline;">12.4</font>, as applicable, a Shareholder shall, within thirty&#160;(30) days after the occurrence of the event giving rise to such right (except in the case of the put option pursuant to <font style="text-decoration:underline;">Section&#160;12.4</font> where such thirty (30) day period shall not apply), provide to the other Shareholder written notice of such exercise.&nbsp;&nbsp;Notwithstanding the foregoing, in the event of the occurrence of any Dissolution Event referred to in clause (ii) or (iii) of <font style="text-decoration:underline;">Section&#160;19.1</font> with respect to any of the Financial Years 2016 through 2020 (inclusive), the period for Mitsui to exercise its sale rights under <font style="text-decoration:underline;">Section&#160;12.3</font> shall end within thirty&#160;(30) days after the date on which the Company provides to Mitsui, in accordance with <font style="text-decoration:underline;">Section&#160;9.4.1(i)</font>, the annual audited Financial Statements for the relevant Financial Year(s) in respect of which such Dissolution Event occurred.&nbsp;&nbsp;<font style="color:#000000;">The sale and purchase of the applicable Shares with respect to any such Transfer of Shares </font>shall occur, subject to obtaining any required Consents, within thirty&#160;(30) days after the date the applicable Shareholder delivered to the other Shareholder the notice referred to in the preceding sentence, but the purchase price due to the selling Shareholder shall be payable (i) with respect to any Shares sold under <font style="text-decoration:underline;">Section&#160;</font>12.1, on the date of the purchase and sale of such Shares, and (ii)&#160;with respect to any Shares sold under <font style="text-decoration:underline;">Section&#160;12.2</font>, <font style="text-decoration:underline;">12.3</font> <font style="text-decoration:underline;">or</font> <font style="text-decoration:underline;">12.4</font>, no later than the first anniversary of the date on which the purchase and sale of such Shares occurred (except that, with respect to any Shares sold under <font style="text-decoration:underline;">Section 12.2</font> or <font style="text-decoration:underline;">Section&#160;12.4</font>, the amounts corresponding to (x)&#160;Mitsui&#8217;s capital contributions as set forth in <font style="text-decoration:underline;">Section&#160;5.1.2</font> and (y)&#160;Mitsui&#8217;s additional capital contribution as set forth in <font style="text-decoration:underline;">Section&#160;</font>5.1.3(a) (to the extent such additional capital contribution has been made in accordance with such Section) shall not be payable as provided in this clause (ii) but shall, instead, be payable in accordance with the preceding clause (i)).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101340"></a><font style="text-decoration:underline;">Loans; Guarantees</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The parties acknowledge that the BioAmber Parties are negotiating certain, and may in the future negotiate further, loans and grants from Canadian governmental institutions to finance the Company, on the terms and conditions provided in this Agreement.&nbsp;&nbsp;For the avoidance of doubt, the parties agree that all such loans or other forms of financing that may be secured for the Company, and any guarantees thereof that Mitsui may be required to provide in accordance with <font style="text-decoration:underline;">Section&#160;5.1.4</font>, shall not, and the BioAmber Parties shall </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">38</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">negotiate the ag</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">reements providing for such loans or other forms of financing and any guarantees thereof so that they do not, prevent or in any manner restrict the exercise and execution of any of the put options to which Mitsui is entitled under this </font><font style="text-decoration:underline;">Section&#160;</font><font style="text-decoration:underline;">12</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> or </font><font style="text-decoration:underline;">Section&#160;</font><font style="text-decoration:underline;">18.2</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> in accordance with their respective terms.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M354"></a><a name="_DV_M355"></a><a name="_Ref302028899"></a><a name="_Toc444101341"></a>CLOSING OF SHARE TRANSFERS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M356"></a><a name="_DV_M357"></a><a name="_Toc444101342"></a><a name="_Ref248596657"></a><font style="text-decoration:underline;">Time and Place</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The closing of any Transfer of Shares pursuant to Section <font style="text-decoration:underline;">11.1.3</font>, <font style="text-decoration:underline;">11.2.1</font>, <font style="text-decoration:underline;">11.4.3</font> (if the purchaser of such Shares is BioAmber), <font style="text-decoration:underline;">12</font>, <font style="text-decoration:underline;">18.2.3</font> or <font style="text-decoration:underline;">19.3</font> shall take place at the offices of the Company within the period therefor specified herein or at such other time and place as the parties to such Transfer may agree.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M358"></a><a name="_Toc444101343"></a><font style="text-decoration:underline;">Closing Deliveries</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;At such closing, (i) the Shareholder that is transferring Shares shall deliver certificates representing such Shares, accompanied by duly executed instruments of transfer; (ii) the Shareholder purchasing such Shares shall deliver at such closing (or such other applicable date in accordance with <font style="text-decoration:underline;">Section&#160;12.5</font>) an amount equal to the aggregate purchase price determined in accordance with the relevant provisions hereof, by wire transfer in immediately available funds to an account designated by the transferring Shareholder; and (iii) all of the parties to such Transfer shall execute such additional documents as may be necessary or appropriate to effect such Transfer.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M359"></a><a name="_Toc444101344"></a><font style="text-decoration:underline;">No Encumbrances; Transfer Taxes</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">. The Shares transferred pursuant to this <font style="text-decoration:underline;">Section&#160;13</font> shall be free and clear of any Encumbrance (other than Encumbrances arising hereunder or attributable to actions by the purchasing Shareholder).&nbsp;&nbsp;Stamp duties or transfer taxes or fees, if any, payable on the Transfer of any such Shares shall be borne and paid by the party required to pay such duty, taxes or fees in accordance with Applicable Law or as the parties to such Transfer may otherwise agree.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M360"></a><a name="_Toc444101345"></a><a name="_Ref302068020"></a><font style="text-decoration:underline;">Effect of Share Transfer</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M361"></a>.&nbsp;&nbsp;This Agreement shall cease to have effect with respect to any Person who is no longer a Shareholder, except that such Person shall continue to be bound, as applicable, by the provisions of this <font style="text-decoration:underline;">Section 13.4</font>, <font style="text-decoration:underline;">Sections 15</font>, <font style="text-decoration:underline;">17.1</font>, <font style="text-decoration:underline;">17.4</font>, <font style="text-decoration:underline;">21</font>, <font style="text-decoration:underline;">22</font> and <font style="text-decoration:underline;">23</font><a name="_DV_M361"></a>.&nbsp;&nbsp;For the avoidance of doubt, nothing in this <font style="text-decoration:underline;">Section 13.4</font> shall be deemed to release a Person who is no longer a Shareholder from any liability for any breach of this Agreement prior to the date such Persons ceased to be a Shareholder.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M362"></a><a name="_DV_M363"></a><a name="_Ref302029057"></a><a name="_Ref377384018"></a><a name="_Toc444101346"></a>PREEMPTIVE RIGHTS, OVERSUBSCRIPTION RIGHTS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M364"></a><a name="_Toc444101347"></a><a name="_Ref243821153"></a><a name="_Ref302029241"></a><a name="_Ref302492682"></a><a name="_Ref243821015"></a><font style="text-decoration:underline;">Restrictions</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The Company shall not issue any Equity Securities of any type or class (including any Shares) to any Person (the &#8220;<font style="font-weight:bold;font-style:italic;">Proposed Recipient</font>&#8221;) unless the Company has offered each Shareholder in accordance with the provisions of this <font style="text-decoration:underline;">Section 14</font>, the right to purchase (or have its designated Permitted Transferee purchase) such Shareholder&#8217;s Pro Rata Share of such issuance (&#8220;<font style="font-weight:bold;font-style:italic;">Preemptive Rights</font>&#8221;) and the right to oversubscribe (or have its designated Permitted Transferee oversubscribe) if the other Shareholder elects not to purchase its Pro Rata Share of such securities (&#8220;<font style="font-weight:bold;font-style:italic;">Oversubscription Rights</font>&#8221;) for a per unit consideration equal to the per unit consideration to be paid by the Proposed Recipient and otherwise on the same terms and conditions </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">39</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">as are offered to the Proposed Recipient (subject to </font><font style="text-decoration:underline;">Section 5.3)</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The Equity Securities that have not been purchased by a Shareholder (or its design</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ated Permitted Transferee) who fails to exercise its Preemptive Rights or fails to complete the purchase of its Pro Rata Share shall first be offered to the Shareholder who has exercised its Oversubscription Rights (on behalf of itself or its designated Pe</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">rmitted Transferee) within the Issuance Notice Period (as defined below) pro rata to the number of additional Equity Securities that such Shareholder (or its designated Permitted Transferee) has agreed to take up above its Pro Rata Share; </font><font style="font-style:italic;">provided</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> that no </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Shareholder shall be obligated to purchase more Equity Securities above its Pro Rata Share than such additional Equity Securities it indicates its agreement to take up under this </font><font style="text-decoration:underline;">Section 14.1</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The restrictions under this </font><font style="text-decoration:underline;">Section 14.1</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> shall not apply to th</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">e following cases or in respect of:&nbsp;&nbsp;(a) any issuance of Equity Securities in connection with any share split, share dividend or other similar event, (b) subject to </font><font style="text-decoration:underline;">Section 8.1.3</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, any issuance of Equity Securities pursuant to the acquisition of another Per</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">son by the Company by consolidation, merger, purchase of assets or other reorganization in which the Company acquires, in a single transaction or series of related transactions, all or substantially all assets of such other Person, or Control of such other</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> Person ((a) or (b), a &#8220;</font><font style="font-weight:bold;font-style:italic;">Permitted Issuance</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221;), or (c) any Defaulting Shareholder (who shall not have Preemptive Rights or Oversubscription Rights).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M365"></a><a name="_Toc444101348"></a><a name="_Ref248139138"></a><font style="text-decoration:underline;">Notice</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Not less than forty five&#160;(45) days prior to a proposed issuance of Equity Securities other than a Permitted Issuance (a &#8220;<font style="font-weight:bold;font-style:italic;">Proposed Issuance</font>&#8221;), the Company shall deliver to each Shareholder written notice of the Proposed Issuance setting forth (a) the number, type and terms of the Equity Securities to be issued, (b) the consideration to be received by the Company in connection with the Proposed Issuance and (c) the identity of the Proposed Recipient(s).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M366"></a><a name="_Toc444101349"></a><a name="_Ref243979576"></a><a name="_Ref248306951"></a><font style="text-decoration:underline;">Exercise of Rights</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Within thirty&#160;(30) days following the receipt of the notice referred to in <font style="text-decoration:underline;">Section 14.2</font> (the &#8220;<font style="font-weight:bold;font-style:italic;">Issuance Notice Period</font>&#8221;), each Shareholder electing to exercise its rights under this <font style="text-decoration:underline;">Section 14</font> shall give written notice to the Company specifying the number of Equity Securities to be purchased by such Shareholder (or its designated Permitted Transferee), the calculation by such Shareholder of its Pro Rata Share and the identity of any designated Permitted Transferee of such Shareholder to exercise the rights of such Shareholder under this <font style="text-decoration:underline;">Section 14</font>.&nbsp;&nbsp;Except as provided in the next succeeding sentence, failure by any Shareholder to give such notice within the Issuance Notice Period shall be deemed a waiver by such Shareholder of its rights under this <font style="text-decoration:underline;">Section 14</font> with respect to such Proposed Issuance.&nbsp;&nbsp;If any Shareholder fails to give the notice required under this <font style="text-decoration:underline;">Section 14.3</font> solely because of the Company&#8217;s failure to comply with the notice provisions of <font style="text-decoration:underline;">Section 14.2</font>, then the Company shall not issue Equity Securities pursuant to this <font style="text-decoration:underline;">Section 14</font>, and if any Equity Securities are purported to be issued, such issuance of securities shall be null and void.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M367"></a><a name="_DV_M368"></a><a name="_Ref302037375"></a><a name="_Ref302550730"></a><a name="_Toc444101350"></a>NON-COMPETE</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M369"></a><a name="_Toc444101351"></a><a name="_Ref302038157"></a><font style="text-decoration:underline;">Non-Compete</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M370"></a><a name="_DV_M371"></a><a name="_DV_M372"></a>.&nbsp;&nbsp;Mitsui shall not, and shall cause its Affiliates not to, directly or indirectly, compete with the Company or the Initial Plant anywhere in the world for so long as Mitsui holds any Shares of the Company and for a peri<a name="_DV_M370"></a>od of <font style="color:#000000;"><a name="_DV_M371"></a>two&#160;(2) y</font>ears after Mitsui ceases to hold such Shares.&nbsp;&nbsp;For purposes hereof, &#8220;<font style="font-weight:bold;font-style:italic;">compete</font><a name="_DV_M372"></a>&#8221; means to engage in any commercial or manufacturing activities related to crystallized BSA and/or bio-based BDO.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">40</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M373"></a><a name="_Toc444101352"></a><font style="text-decoration:underline;">Exercise of Drag-Along Right</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_C26"></a><a name="_DV_M374"></a>.&nbsp;&nbsp;In the event BioAmb<a name="_DV_C26"></a>er exercises its Drag-Along Right<font style="color:#000000;"><a name="_DV_M374"></a>,</font> the non-compete period set forth in <font style="text-decoration:underline;">Section 15.1</font> shall be reduced to one&#160;(1) year.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">16.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M375"></a><a name="_Toc444101353"></a><a name="_Ref302049564"></a>CERTAIN ADDITIONAL AGREEMENTS AND UNDERTAKINGS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M377"></a><a name="_Toc444101354"></a><font style="text-decoration:underline;">General Shareholder Obligations</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Each Shareholder shall comply with the provisions of this Agreement in relation to the Company, shall exercise its rights and powers with respect thereto in accordance with, and so as to give effect to, this Agreement and shall take all necessary actions to ensure that the Company&#8217;s Charter Documents do not, at any time, conflict with the provisions of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M378"></a><a name="_Toc444101355"></a><font style="text-decoration:underline;">Initial Plant</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Each party shall, within the scope of its rights and obligations set forth in this Agreement, use its reasonable best efforts to cause the Initial Plant to be constructed and commissioned with the capacity (including expanded capacity) set forth in <font style="text-decoration:underline;">Section 3.2</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M379"></a><a name="_Toc444101356"></a>16.3<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Certain Operational Matters</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M380"></a>16.3.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Use of Contributions</font>.&nbsp;&nbsp;The Company shall not use any capital or other contributions from any Shareholder for the purposes of directly or indirectly paying or otherwise satisfying any financial or monetary obligation owed by BioAmber or any BioAmber Affiliate to a third party under any BioAmber IP Agreement, including the payment of any royalties, fees, inventor awards, development costs, or other payments to any owner, inventor, licensor or developer of, or other third party thereunder, except for any payment related to the Technology License Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M381"></a>16.3.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Exclusive Distributor</font>. Except as otherwise agreed in writing by all the Shareholders, the Company shall not appoint any Person (other than a party in accordance with this Agreement) as the exclusive distributor in any geography of BSA and/or BDO produced by the Company.&nbsp;&nbsp;Notwithstanding the above, the Company shall be permitted to appoint exclusive distributors in selected geographies for specific applications using BSA or BDO.&nbsp;&nbsp;The applications will include BSA used as deicers or coolants, solvents, lubricants, flavors and fragrances, food and plasticizers.&nbsp;&nbsp;BioAmber shall consult Mitsui prior to the execution of any such exclusive distribution agreements and such agreements shall not be detrimental to the Company&#8217;s sales or profitability.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M382"></a><a name="_DV_M383"></a>16.3.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Supply Agreements</font>.&nbsp;&nbsp;Except as expressly provided herein or as otherwise approved by (x)&#160;the Board or (y)&#160;a Marketing Committee which the Board may form and to which it may delegate such authority, which Marketing Committee shall consist of at least one (1) member appointed by BioAmber and one (1) member appointed by Mitsui, in each case acting in accordance with the Marketing Policy, the Company shall not enter into any Contract that obligates the Company to supply to a third party any portion of the BSA and/or BDO produced by the Company.&nbsp;&nbsp;For the avoidance of doubt, the foregoing sentence shall not apply to contracts signed by BioAmber prior to the date of this Agreement that were disclosed to Mitsui prior to such date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">41</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">16.3.4</font><font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BioAmber IP</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;BioAmber shall not, and shall cause its Affiliates not to (a)&#160;abandon, dedicate to the public, fail to enforce, or otherwise allow to la</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">pse any BioAmber IP that is a Registered IP Asset, (b) terminate, willfully or negligently breach, or allow to expire any BioAmber IP Agreement, or (c) take any other action that is reasonably likely to adversely affect or impede the ability of the Company</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> to use and exploit, in each case as contemplated or otherwise set forth in this Agreement and any Ancillary Agreement, any BioAmber Technology or other Intellectual Property Rights owned, co- or jointly owned, held by or licensed by BioAmber or any BioAmb</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">er Affiliate necessary, useful, or otherwise related to (i) the operation of the Business by the Company, (ii) the building, operation and exploitation of the Additional Plant in accordance with </font><font style="text-decoration:underline;">Section 4</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, or (iii) the production, use, sale and commercial </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">exploitation of BSA and/or BDO by the parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M384"></a>16.3.5<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Company Support</font>.&nbsp;&nbsp;If, during the term of this Agreement, the Company becomes unable to continue to use or practice under any Intellectual Property Rights licensed by BioAmber or any Affiliate thereof to the Company pursuant to the Technology License Agreement in accordance with the terms thereof as a result of (a) the expiration, termination or breach of any BioAmber IP Agreement by the BioAmber Parties or any BioAmber Affiliate or (b) the abandonment, invalidation or failure to enforce such Intellectual Property Rights by BioAmber or the applicable licensor of such Intellectual Property Rights, then BioAmber shall use its best efforts to acquire a license to, or otherwise obtain all necessary rights in and to, such Intellectual Property Rights, or other Intellectual Property Rights as the Shareholders may reasonably agree, to the extent reasonably necessary for the Company to continue to operate the Business, and BioAmber shall promptly license or cause to be licensed to the Company such Intellectual Property Rights upon the terms and conditions of the Technology License Agreement or as the Shareholders may reasonably agree.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M385"></a><a name="_Toc444101357"></a><font style="text-decoration:underline;">Additional Agreements</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The parties acknowledge that:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M386"></a><a name="_DV_M387"></a><a name="_Ref302494300"></a><a name="_DV_C30"></a>16.4.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Trademark License Agreement</font><a name="_DV_C30"></a>.&nbsp;&nbsp;BioAmber, as licensor, and the Company, as licensee, have entered into a trademark license agreement, dated as of September 24, 2015 (the &#8220;<font style="font-weight:bold;font-style:italic;">Trademark License Agreement</font>&#8221;), which Trademark License Agreement currently remains in effect in accordance with its terms.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M391"></a><a name="_DV_M392"></a><a name="_Ref302494333"></a>16.4.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BioAmber Services Agreement</font>.&nbsp;&nbsp;Promptly after the date hereof, BioAmber and Mitsui may enter into good faith negotiations in respect of a services agreement in connection with the non-financial contributions of BioAmber to the Company pursuant to <font style="text-decoration:underline;">Section&#160;6.1</font>, to be executed between BioAmber and the Company, on terms and conditions to be agreed upon between BioAmber and Mitsui (the &#8220;<font style="font-weight:bold;font-style:italic;">BioAmber Services Agreement</font>&#8221;), which&nbsp;&nbsp;BioAmber Services Agreement (if so agreed between such parties) the Company agrees it will duly execute and deliver.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M393"></a><a name="_DV_M394"></a><a name="_Ref302494357"></a>16.4.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Mitsui Services Agreement</font>.&nbsp;&nbsp;Promptly after the date hereof, BioAmber and Mitsui may enter into good faith negotiations in respect of a services agreement in connection with the non-financial contributions of Mitsui to the Company pursuant to <font style="text-decoration:underline;">Section&#160;6.2</font>, to be executed between Mitsui and the Company, on terms and conditions to be agreed upon between </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">42</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">BioAmber and Mitsui (the &#8220;</font><font style="font-weight:bold;font-style:italic;">Mitsui Services Agreement</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221;), which Mitsui Services Agreement (if so agreed between such parties) the Company agrees it will duly execute and deliver.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M395"></a><a name="_DV_M396"></a><a name="_Ref302494407"></a><a name="_DV_M397"></a><a name="_DV_C38"></a><a name="_DV_M398"></a><a name="_DV_C39"></a><a name="_DV_M399"></a>16.4.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Assignment Agreement</font>.<a name="_DV_M397"></a>&nbsp;&nbsp;<a name="_DV_C38"></a>BioAmber (or its applicable Affiliate)<a name="_DV_M398"></a>, as assignor,<a name="_DV_C39"></a> and the Company<a name="_DV_M399"></a>, as assignee, have entered into an assignment agreement, dated as of July 9, 2015 (the &#8220;<font style="font-weight:bold;font-style:italic;">Assignment Agreement</font>&#8221;), with respect to the Supply Contracts.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M400"></a><a name="_Toc444101358"></a><font style="text-decoration:underline;">Supply Contracts</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;In the event that BioAmber (or any Affiliate thereof, excluding any Affiliate of BioAmber that exploits or operates the Additional Plant or other plants that produce BSA and/or BDO) enters into any Contract for the supply of BSA and/or BDO to any third party, which Contract is not listed as a Supply Contract in <font style="text-decoration:underline;">Schedule 16.5</font> and has not been assigned to the Company pursuant to the Assignment Agreement, BioAmber shall (or shall cause its applicable Affiliate to), after consultation with Mitsui, with the objective of filling the available capacity of the Initial Plant (if any), subject to the terms of such Contract (including any applicable geographical restrictions), (i) add such Contract to the list of Supply Contracts set forth in <font style="text-decoration:underline;">Schedule 16.5</font> and (ii) assign such Contract to the Company pursuant to an agreement in form and substance similar to the Assignment Agreement, or as BioAmber and Mitsui may otherwise agree, it being understood that BioAmber shall not assign any such Contract to the Company if by doing so, the capacity of the Initial Plant would be exceeded at any point during the term of such Contract taking into account the then-existing supply commitments of the Initial Plant.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M401"></a>16.5.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BioAmber Lux&#8217;s Obligations</font>.&nbsp;&nbsp;BioAmber guarantees each and every obligation of BioAmber Lux under this Agreement and any Ancillary Agreement to which BioAmber Lux is or hereafter becomes a party, including each and every representation and warranty of BioAmber Lux hereunder or thereunder, and the full and timely performance of BioAmber Lux&#8217;s obligations under this Agreement and such Ancillary Agreements.&nbsp;&nbsp;This is a guarantee of payment and performance and BioAmber acknowledges and agrees that this guarantee is unconditional.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M402"></a><a name="_DV_M403"></a><a name="_Ref302553237"></a><a name="_Toc444101359"></a>REPRESENTATIONS AND WARRANTIES</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M404"></a><a name="_Toc444101360"></a><a name="_Ref443058271"></a><a name="_Ref443301437"></a><a name="_Ref443302379"></a><font style="text-decoration:underline;">Survival of Representations and Warranties contained in the Original JVA</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The Parties hereby acknowledge and agree that, pursuant to <font style="text-decoration:underline;">Section&#160;17.3</font> of the Original JVA (for clarity, as <font style="text-decoration:underline;">Section 17</font> of the Original JVA was executed as of&nbsp;&nbsp;November 2, 2011 and disregarding any subsequent amendments and restatements thereof) and notwithstanding the execution of this Agreement, the respective representations and warranties of the applicable parties set forth in <font style="text-decoration:underline;">Section 17</font> of the Original JVA shall survive indefinitely and continue in effect as provided for in the Original JVA.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101361"></a><font style="text-decoration:underline;">BioAmber Parties&#8217; Representations and Warranties</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The BioAmber Parties hereby jointly and severally represent to Mitsui as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M405"></a><a name="_DV_M406"></a>17.2.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Organization, Good Standing</font>.&nbsp;&nbsp;Each of the BioAmber Parties and the Company is a corporation or another Entity duly organized, validly existing and in good standing under the laws of its jurisdiction of organization.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">43</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M407"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">17.2.2</font><font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Authority; Binding Nature of Agreements</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Each of the </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">BioAmber Parties, the Company and any other applicable BioAmber Affiliate has, or prior to its execution will have, all requisite corporate (or other applicable Entity) power and authority to execute and deliver this Agreement and each Ancillary Agreement </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">to which it is, or it will become, a party and to carry out the provisions of this Agreement and such Ancillary Agreements.&nbsp;&nbsp;The execution, delivery and performance by each of the BioAmber Parties, the Company and any other applicable BioAmber Affiliate of</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> this Agreement and each of the Ancillary Agreements to which it is, or it will become, a party have been, or prior to its execution will be, approved by all requisite action on the part of each such party, its board of directors and shareholders.&nbsp;&nbsp;BioAmbe</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">r has delivered, or prior to its execution will deliver, to Mitsui true and complete copies of the resolutions adopted by its board of directors and shareholders approving the execution, delivery and performance of this Agreement, the Ancillary Agreements </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">to which it is or it will become a party and the transactions contemplated hereby and thereby.&nbsp;&nbsp;Each of the BioAmber Parties and the Company has duly and validly executed and delivered this Agreement and each Ancillary Agreement to which it is a party, and</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> it (or its applicable Affiliate) will duly and validly execute and deliver each other Ancillary Agreement to which it will become a party.&nbsp;&nbsp;Each of this Agreement and the Ancillary Agreements to which each of the BioAmber Parties, the Company and any othe</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">r applicable BioAmber Affiliate is or will become a party constitutes, or upon its execution will constitute, the legal, valid and binding obligation of each such party, enforceable against such party in accordance with its terms, except as may be limited </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">by bankruptcy, insolvency, reorganization, moratorium and other similar laws and equitable principles related to or limiting creditors&#8217; rights generally and by general principles of equity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M408"></a><a name="_Ref302550836"></a><a name="_DV_M409"></a>17.2.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">No Conflicts; Consents</font>.&nbsp;&nbsp;The execution, delivery and performance of this Agreement or any Ancillary Agreement by each of the BioAmber Parties, the Company and any other applicable BioAmber Affiliate do not and will not (with or without notice or lapse of time) (a) conflict with, violate or result in any breach of (i) any of the provisions of such party&#8217;s Charter Documents; (ii) any resolutions adopted by such party&#8217;s shareholders, board of directors or committees thereof; (iii) any Applicable Law; or (iv) any provision of any Contract; (b) give any Governmental Authority or other Person the right to (i) challenge the transactions contemplated hereby or thereby; (ii) exercise any remedy or obtain any relief under any Applicable Law to which any of the BioAmber Parties, the Company or any other applicable BioAmber Affiliate, or any of their respective assets, is subject; (iii) declare a default of, exercise any remedy under, accelerate the performance of, cancel, terminate, modify or receive any payment under any Contract; or (iv)&#160;revoke, suspend or modify any Consent; (c) result in the imposition or creation of any Encumbrance upon or with respect to any of its assets or properties; or (d) require any of the BioAmber Parties, the Company or any other applicable BioAmber Affiliate to obtain any Consent or make or deliver any f<a name="_DV_M409"></a>iling or notice to a Governmental Authority.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M410"></a><a name="_DV_M411"></a>17.2.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">No Proceedings</font>.&nbsp;&nbsp;There is no Proceeding pending or, to the BioAmber Parties&#8217; knowledge, threatened against or affecting any of the BioAmber Parties or the Company, any of their respective properties, assets, operations or businesses, or the BioAmber Parties&#8217; or the Company&#8217;s respective rights relating thereto, that could materially and adversely affect the business or operations of any such party (including, in the case of the Company, the Business) or its ability to fulfill its obligations hereunder, and to the BioAmber Parties&#8217; knowledge, no event </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">44</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">has occurred, and no condition or circumstance exists, that might give rise to or serve as a basis for the commencement of any such Proceeding.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M412"></a><a name="_DV_M426"></a><a name="_Toc444101362"></a><font style="text-decoration:underline;">Mitsui&#8217;s Representations and Warranties</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Mitsui hereby represents to the BioAmber Parties as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M427"></a>17.3.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Organization; Valid Existence</font>.&nbsp;&nbsp;Mitsui is a corporation duly organized and validly existing under the laws of Japan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M428"></a>17.3.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Authority; Binding Nature of Agreements</font>.&nbsp;&nbsp;Mitsui has, or prior to its execution will have, all requisite corporate power and authority to execute and deliver this Agreement and each Ancillary Agreement to which it is, or it will become, a party and to carry out the provisions of this Agreement and such Ancillary Agreements.&nbsp;&nbsp;The execution, delivery and performance by Mitsui of this Agreement and the Ancillary Agreements to which it is, or it will become, a party have been, or prior to its execution will be, approved by all requisite action on the part of each such party.&nbsp;&nbsp;Mitsui has duly and validly executed and delivered this Agreement and each Ancillary Agreement to which it a party, and it will duly and validly execute and deliver each other Ancillary Agreement to which it will become a party.&nbsp;&nbsp;Each of this Agreement and the Ancillary Agreements to which Mitsui is or will become a party constitutes, or upon its execution will constitute, the legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws and equitable principles related to or limiting creditors&#8217; rights generally and by general principles of equity.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M429"></a>17.3.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">No Conflicts; Consents</font>.&nbsp;&nbsp;The execution, delivery and performance of this Agreement or any Ancillary Agreement by Mitsui do not and will not (with or without notice or lapse of time) (a) conflict with, violate or result in any breach of (i) any of the provisions of such party&#8217;s Charter Documents; (ii) any resolutions adopted by such party&#8217;s shareholders, board of directors or committees thereof; (iii) any Applicable Law; or (iv) any provision of any Contract; (b) give any Governmental Authority or other Person the right to (i) challenge the transactions contemplated hereby or thereby; (ii) exercise any remedy or obtain any relief under any Applicable Law to which Mitsui, or any of its assets, is subject; (iii) declare a default of, exercise any remedy under, accelerate the performance of, cancel, terminate, modify or receive any payment under any Contract; or (iv) revoke, suspend or modify any Consent; (c) result in the imposition or creation of any Encumbrance upon or with respect to any of its assets or properties; or (d) require Mitsui to obtain any Consent or make or deliver any filing or notice to a Governmental Authority.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M430"></a>17.3.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">No Proceedings</font>.&nbsp;&nbsp;There is no Proceeding pending or, to Mitsui&#8217;s knowledge, threatened against or affecting Mitsui, any of its properties, assets, operations or businesses, or its rights relating thereto, that could materially and adversely affect the business or operations of such party or its ability to fulfill its obligations hereunder, and to Mitsui&#8217;s knowledge, no event has occurred, and no condition or circumstance exists, that might give rise to or serve as a basis for the commencement of any such Proceeding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">45</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M431"></a><a name="_Toc444101363"></a><a name="_Ref302550853"></a><font style="text-decoration:underline;">Survival of Representations and Warranties</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M432"></a><a name="_DV_M432"></a>. The respective representations and warranties of the applicable parties set forth in this <font style="text-decoration:underline;">Section 17</font> shall survive indefinitely and continue in effect notwithstanding the termination of this Agreement.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">18.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M433"></a><a name="_Toc444101364"></a><a name="_Ref164405316"></a><a name="_Ref164405316"></a>DEFAULT</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M434"></a><a name="_Toc444101365"></a>18.1<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Events of Default</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M435"></a><a name="_DV_M436"></a><a name="_Ref302030377"></a>18.1.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Events of Default</font>.&nbsp;&nbsp;Each of the following events constitutes an &#8220;<font style="font-weight:bold;font-style:italic;">Event of Default</font>&#8221; with respect to a Shareholder, it being understood that if such Shareholder is (x)&#160;BioAmber Lux or a Permitted Transferee thereof (other than BioAmber), the occurrence of any such event with respect to BioAmber shall constitute an Event of Default with respect to BioAmber Lux or such Permitted Transferee, as applicable, or (y) a Permitted Transferee of Mitsui, the occurrence of any such events with respect to Mitsui shall constitute an Event of Default with respect to such Permitted Transferee:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M437"></a><a name="_Ref164416383"></a>(a)<font style="margin-left:144pt;"></font>such Shareholder makes a general assignment for the benefit of creditors;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M438"></a>(b)<font style="margin-left:144pt;"></font>the appointment of a conservator, custodian, receiver, trustee or similar official for such Shareholder or its assets;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M439"></a><a name="_Ref443039834"></a><a name="_DV_M440"></a>(c)<font style="margin-left:144pt;"></font>any voluntary or involuntary bankruptcy, insolvency, reorganization, debt adjustment, dissolution, liquidation, receivership or other debt relief proce<a name="_DV_M440"></a>edings is commenced (and not dismissed or otherwise terminated) in respect of such Shareholder (excluding, for the avoidance of doubt, any bona fide corporate reorganization not involving debt relief or insolvency issues); or</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M441"></a><a name="_DV_M442"></a>(d)<font style="margin-left:144pt;"></font>such Shareholder materially br<a name="_DV_M442"></a>eaches this Agreement or any of the Ancillary Agreements and such breach, if of a nature that can be cured, remains uncured thirty&#160;(30) days after such Shareholder received notice thereof from the other Shareholder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M443"></a><a name="_Ref301975022"></a><a name="_Ref302033307"></a><a name="_Ref174589273"></a><a name="_Ref174587347"></a><a name="_DV_M444"></a>18.1.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Suspension of Certain Rights Upon an Event of Default</font><a name="_DV_M444"></a>.&nbsp;&nbsp;In addition to other limitations on a Defaulting Shareholder&#8217;s rights set forth elsewhere in this Agreement, u<font style="color:#000000;">pon the occurrence of an Event of Default and for so long as such Event of Default has not been remedied to the reasonable satisfaction of the Shareholder other than the Defaulting Shareholder, and notwithstanding anything to the contrary set forth herein, (i) the presence of the Defaulting Shareholder shall not be required to constitute quorum at any Shareholders&#8217; meeting; (ii) the Defaulting Shareholder shall not have the right to vote in respect of any matter reserved for the approval of the Shareholders pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 8.1.2</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">8.1.3</font><font style="color:#000000;"> (which matter may be approved solely by the non-Defaulting Shareholder); (iii) the presence of the Defaulting Shareholder&#8217;s nominee(s) to the Board shall not be required to constitute quorum at any Board meeting; (iv) the Defaulting Shareholder&#8217;s nominee(s) to the Board shall not have the right to vote in respect of any matter subject to Board approval (which matter may be approved solely by the non-Defaulting </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">46</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="color:#000000;">Shareholder&#8217;s nominee(s) to the Board); and (v) the Defaulting Shareholder shall have no right to receive dividends or other distributions from the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M445"></a><a name="_Ref174591171"></a><a name="_Toc444101366"></a>18.2<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Option to Buy/Sell Upon an Event of Default</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M446"></a><a name="_Ref174590031"></a>18.2.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;color:#000000;">BioAmber Call Option Upon Mitsui Event of Default</font><font style="color:#000000;">.&nbsp;&nbsp;If an Event of Default occurs and is continuing and Mitsui is the Defaulting Shareholder, BioAmber Lux shall have the right to purchase the Shares held by Mitsui (and any Permitted Transferee thereof) at a purchase price equal to seventy five percent (75%) of the </font><font style="font-style:italic;color:#000000;">lesser</font><font style="color:#000000;"> of (i) the Fair Market Value of such Shares (calculated in accordance with </font><font style="text-decoration:underline;color:#000000;">Section 5.3.2</font><font style="color:#000000;"> applied </font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;"> hereto) and (ii) the Book Value of such Shares, in each case calculated on the date BioAmber Lux delivered the Default Option Exercise Notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M447"></a><a name="_Ref443059178"></a><a name="_Ref302035350"></a>18.2.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">BioAmber Put Option Upon Mitsui Event of Default</font>.&nbsp;&nbsp;If an Event of Default (excluding therefrom, for purposes hereof, the event referred to in clause (d) of <font style="text-decoration:underline;">Section&#160;18.1.1</font>; <font style="font-style:italic;">provided, however</font>, that if and for so long as Mitsui&#8217;s Pro Rata Share is equal to more than forty-five percent (45%), the foregoing exclusion shall not apply and the event referred to in clause (d) of <font style="text-decoration:underline;">Section&#160;18.1.1</font> shall also be included as an Event of Default for purposes of this <font style="text-decoration:underline;">Section&#160;18.2.2</font>) occurs and is continuing and Mitsui is the Defaulting Shareholder, BioAmber Lux<font style="color:#000000;"> shall, alternatively to its right under </font><font style="text-decoration:underline;color:#000000;">Section&#160;18.2.1</font><font style="color:#000000;">, have the right to sell to Mitsui </font>the Shares held by BioAmber Lux (and any Permitted Transferee thereof)<font style="color:#000000;"> at a purchase price equal to one hundred twenty five percent (125%) of the </font><font style="font-style:italic;color:#000000;">greater</font><font style="color:#000000;"> of (i) the Fair Market Value of such Shares (calculated in accordance with </font><font style="text-decoration:underline;color:#000000;">Section 5.3.2</font><font style="color:#000000;"> applied </font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;"> hereto) and (ii) the Book Value of such Shares, in each case calculated on the date </font>BioAmber Lux<font style="color:#000000;"> delivered the Default Option Exercise Notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref375162689"></a>18.2.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Mitsui Put Option Upon BioAmber Event of Default</font>.&nbsp;&nbsp;If an Event of Default occurs and is continuing and a BioAmber Party is the Defaulting Shareholder, <font style="color:#000000;">Mitsui shall have the right to sell to BioAmber Lux </font>the Shares held by Mitsui (and any Permitted Transferee thereof)<font style="color:#000000;"> at a purchase price equal to one hundred twenty five percent (125%) of the </font><font style="font-style:italic;color:#000000;">greater</font><font style="color:#000000;"> of (i) the Fair Market Value of such Shares (calculated in accordance with </font><font style="text-decoration:underline;color:#000000;">Section 5.3.2</font><font style="color:#000000;"> applied </font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;"> hereto) and (ii) the Book Value of such Shares, in each case calculated on the date Mitsui delivered the Default Option Exercise Notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M448"></a><a name="_Ref375162793"></a><a name="_Ref174587159"></a><a name="_Ref302492140"></a>18.2.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Mitsui Call Option Upon BioAmber Event of Default</font>.&nbsp;&nbsp;If an Event of Default (excluding therefrom, for purposes hereof, the event referred to in clause (d) of <font style="text-decoration:underline;">Section&#160;18.1.1</font>; <font style="font-style:italic;">provided, however</font>, that if and for so long as Mitsui&#8217;s Pro Rata Share is equal to more than forty-five percent (45%), the foregoing exclusion shall not apply and the event referred to in clause (d) of <font style="text-decoration:underline;">Section&#160;18.1.1</font> shall also be included as an Event of Default for purposes of this <font style="text-decoration:underline;">Section&#160;18.2.4</font>) occurs and is continuing and a BioAmber Party is the Defaulting Shareholder, Mitsui shall, <font style="color:#000000;">alternatively</font> to its right under <font style="text-decoration:underline;">Section&#160;18.2.3</font>, have the right to purchase the Shares held by BioAmber Lux (and any Permitted Transferee thereof) at a purchase price equal to seventy five percent (75%) of the <font style="font-style:italic;">lesser</font> of (i) the Fair Market Value of such Shares (calculated in accordance with <font style="text-decoration:underline;">Section 5.3.2</font> applied <font style="font-style:italic;">mutatis mutandis</font> hereto) and (ii) the Book Value of such Shares, in each case calculated on the date Mitsui delivered the Default Option Exercise Notice.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">47</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M449"></a><a name="_DV_M450"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">18.2.5</font><font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Exercise of Rights; Closing</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;To exercise its purchase or sale rights under Section </font><font style="text-decoration:underline;">18.2.1</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, </font><font style="text-decoration:underline;">18.2.2</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">18.2.3</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> or </font><font style="text-decoration:underline;">18.2.4</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, as applicable, the non-Defaulting Shareholder shall provide notice thereof to the Defaulting Shareholder (the &#8220;</font><font style="font-weight:bold;font-style:italic;">Default Option Exercise Notice</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M449"></a>&#8221;).</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M450"></a> </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> </font><font style="color:#000000;">The closing of any such Transfer of Shares </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">shall occur, subject to obtaining any required </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Consents, within thirty&#160;(30) days after the date the applicable Shareholder delivered to the Defaulting Shareholder the Default Option Exercise Notice.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">19.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M451"></a><a name="_Ref174596620"></a><a name="_Toc444101367"></a><a name="_Ref162085612"></a>DISSOLUTION</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M452"></a><a name="_Toc444101368"></a><a name="_Ref174591557"></a><a name="_Ref302469139"></a><a name="_Ref368663726"></a><font style="text-decoration:underline;">Dissolution Events</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M453"></a>.&nbsp;&nbsp;In the event that (i) the Operational Date does not occur by January 31, 2016; (ii) the cumulative losses of the Company accrued during the Financial Years from and after January 1, 2016 exceed seventy-five percent (75%) of its paid-in capital; (iii) the Company earns no after-tax profit in any three&#160;(3) consecutive Financial Years from and after January 1, 2016; (iv) the Company becomes unable to pay its debts generally as they become due or subject to a bankruptcy, insolvency or other analogous proceeding; or (v) there occurs any other dissolution event in respect of the Company provided for under Applicable Law (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Dissolution Event</font>&#8221;), each Shareholder shall have the right (subject, in the case of BioAmber Lux, to the rights of Mitsui under <font style="text-decoration:underline;">Section&#160;</font>12.3) by providing written notice to the other Shareholder (the &#8220;<font style="font-weight:bold;font-style:italic;">Dissolution Notice</font>&#8221;), to cause the Company to be dissolved and liquidated, whereupon the Shareholders shall cooperate and take all necessary steps for dissolving and liq<a name="_DV_M453"></a>uidating the Company in accordance with Applicable Law and terminating their respective contractual obligations therewith.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M454"></a><a name="_Toc444101369"></a><font style="text-decoration:underline;">Distribution of Remaining Assets</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Unless otherwise agreed by the Shareholders, any assets and property of the Company remaining after such liquidation shall be allocated and distributed to the Shareholders in accordance with their then respective Pro Rata Shares.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M455"></a><a name="_Toc444101370"></a><a name="_Ref302063633"></a><font style="text-decoration:underline;">Right to Prevent Dissolution</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Notwithstanding the provisions of <font style="text-decoration:underline;">Section 19.1</font>, the Company shall not be so dissolved and liquidated if, upon the occurrence of a Dissolution Event, (i) a Shareholder opposes the dissolution and liquidation requested by the other Shareholder and (ii) such Shareholder opposing the dissolution and liquidation agrees to purchase the Shares held by the other Shareholder (and any Permitted Transferee thereof) at a purchase price equal to one hundred percent (100%) of the Book Value of such Shares calculated on the date of such agreement.&nbsp;&nbsp;The closing of such Transfer of Shares shall occur, subject to obtaining any required Consents, within thirty&#160;(30) days after the date of such agreement.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">20.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M456"></a><a name="_DV_M457"></a><a name="_Ref302037321"></a><a name="_Toc444101371"></a><a name="_DV_M458"></a><font style="text-transform:none;"><a name="_DV_M458"></a>TERMINATION</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M459"></a><a name="_Toc444101372"></a><a name="_Ref302037482"></a><font style="text-decoration:underline;">Termination of the Agreement</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;This Agreement shall become effective from its date and shall continue in effect until (a) any date agreed upon in writing by all of the parties, (b) the Company is liquidated, dissolved or wound-up or (c) there is only one&#160;(1) Shareholder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M460"></a><a name="_Toc444101373"></a><a name="_Ref245618365"></a><a name="_Ref302551377"></a><font style="text-decoration:underline;">Consequences of Termination</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;If this Agreement is terminated pursuant to <font style="text-decoration:underline;">Section 20.1</font>, this Agreement shall have no further force and effect, except that the parties shall continue to be bound, as applicable, by the provisions of this <font style="text-decoration:underline;">Section 20</font>, <font style="text-decoration:underline;">Sections 8.2.13</font>, <font style="text-decoration:underline;">15</font>, <font style="text-decoration:underline;">17.1</font>, <font style="text-decoration:underline;">17.4</font>, <font style="text-decoration:underline;">21</font>, </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">48</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">22</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> and </font><font style="text-decoration:underline;">23</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;For the avoidance of doubt, nothing in this </font><font style="text-decoration:underline;">Section 20</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> shall be deemed to release any party from any liability for a</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ny breach of this Agreement prior to the effective date of such termination.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">21.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M461"></a><a name="_DV_M462"></a><a name="_Ref302058690"></a><a name="_Toc444101374"></a>INDEMNIFICATION</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M463"></a><a name="_DV_M464"></a><a name="_Toc444101375"></a><font style="text-decoration:underline;">General Indemnification</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Subject to, in the case of the Company, any applicable indemnification obligation of the Company to the Directors pursuant to the Indemnification Agreement, each party shall indemnify, defend and hold harmless each other party, its Affiliates and its and their respective directors, officers, employees, agents and advisors from and against any Loss arising out, relating to or resulting from any breach by such party of any representation or warranty, or covenant, agreement or undertaking, contained in this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M465"></a><a name="_Toc444101376"></a><font style="text-decoration:underline;">IP Indemnification</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;BioAmber, on behalf of itself and its Affiliates, shall indemnify, defend and hold harmless each of Mitsui and the Company, its respective Affiliates and its and their respective directors, officers, employees, agents and advisors from and against any Loss arising out, relating to or resulting from the Company&#8217;s use of, and the exercise of any rights licensed by BioAmber or any Affiliate thereof to the Company in and to, any BioAmber Technology, including with respect to the operation of the Business generally and the production, sale and use of BSA and/or BDO.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M466"></a><a name="_Toc444101377"></a><font style="text-decoration:underline;">No Consequential Damages</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Notwithstanding anything to the contrary in this <font style="text-decoration:underline;">Section 21</font>, to the maximum extent permitted by Applicable Law, no party shall be liable under this Agreement to any Person for any indirect, incidental, punitive, exemplary or consequential damages; <font style="font-style:italic;">provided, however</font>, that the foregoing shall not be construed to preclude recovery by any party in respect of Losses incurred from third party claims.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">22.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M467"></a><a name="_DV_M468"></a><a name="_Ref162083216"></a><a name="_Ref302059157"></a><a name="_Toc444101378"></a>DISPUTE RESOLUTION</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M469"></a><a name="_Toc444101379"></a><a name="_Ref162083164"></a><a name="_Ref164592515"></a><a name="_Ref302060957"></a><font style="text-decoration:underline;">Escalation Procedure</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M470"></a><a name="_DV_M471"></a>.&nbsp;&nbsp;Any dispute, controversy, claim or disagreement between or among any parties (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Dispute</font><a name="_DV_M470"></a>&#8221;) arising out of this Agreement, its interpretation or the performance by any party of its obligations hereunder, including any questions regarding the existence, validity or termination hereof, shall be resolved pursuant to this <font style="text-decoration:underline;">Section 22</font>.&nbsp;&nbsp;For clarity, any disagreement related to the matters set forth in <font style="text-decoration:underline;">Section 8.1.2</font> shall be subject to the BioAmber Right to Approve set forth in the proviso included in such Section.&nbsp;&nbsp;Any Dispute that the relevant parties are unable to resolve through amicable negotiations shall be submitted by the parties for further review and discussion to designated senior representatives of each such party with authority to reach an agreement in connection with such Dispute.&nbsp;&nbsp;Such designated senior representatives shall meet or otherwise confer as promptly as practicable, and endeavor in good faith to resolve the Dispute.&nbsp;&nbsp;If such designated senior representatives are unable to reach an agreement to resolve the Dispute within ten&#160;(10) days after their initial meeting, then the Dispute shall be resolved pursuant to <font style="text-decoration:underline;"><a name="_DV_M471"></a>Section 22.2</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">49</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M472"></a><a name="_Ref162083539"></a><a name="_Ref162150743"></a><a name="_Ref162151046"></a><a name="_Ref162151102"></a><a name="_Ref302060784"></a><a name="_Toc444101380"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">22.2</font><font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Arbitration</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M473"></a><a name="_Ref302494769"></a><font style="text-decoration:underline;">Rules</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M474"></a>.&nbsp;&nbsp;Any Dispute that is not resolved pursuant to <font style="text-decoration:underline;">Section 22.1</font> shall be finally settled by binding arbitration administered by the ICC, in accordance with the ICC Rules of Arbitration (the &#8220;<font style="font-weight:bold;font-style:italic;">ICC Rules</font>&#8221;) in effect at the time of the arbitration, except as they may be modified herein or by agreement of all the parties to the Dispute.&nbsp;&nbsp;Each party to the arbitration shall be deemed to be an &#8220;<font style="font-weight:bold;font-style:italic;">Arbitration Party</font>&#8221; for purposes of this <font style="text-decoration:underline;">Section 22.2</font><a name="_DV_M474"></a>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M475"></a>22.2.2<font style="margin-left:144pt;"></font><font style="text-decoration:underline;color:#000000;">Place; Language</font><font style="color:#000000;">.&nbsp;&nbsp;The place of arbitration shall be New York, New York, and the proceedings shall be conducted in the English language.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M476"></a><a name="_Ref255918569"></a>22.2.3<font style="margin-left:144pt;"></font><font style="text-decoration:underline;color:#000000;">Tribunal</font><font style="color:#000000;">.&nbsp;&nbsp;The arbitration shall be conducted by three arbitrators (such panel of arbitrators, the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Tribunal</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M477"></a><a name="_Ref255809828"></a>22.2.4<font style="margin-left:144pt;"></font><font style="text-decoration:underline;color:#000000;">Arbitrators&#8211;Two Arbitration Parties</font><font style="color:#000000;">.&nbsp;&nbsp;If there are two Arbitration Parties to the arbitration, each Arbitration Party shall nominate one&#160;(1) arbitrator within thirty&#160;(30) days after delivery of the &#8220;Request for Arbitration&#8221; (as defined in the ICC Rules).&nbsp;&nbsp;In the event an Arbitration Party fails to nominate an arbitrator within this time period, then upon request of either Arbitration Party, such arbitrator shall instead be appointed by the ICC within thirty&#160;(30) days of receiving such request.&nbsp;&nbsp;The two&#160;(2) arbitrators appointed in accordance with the above provisions shall nominate the third arbitrator within thirty&#160;(30) days of the appointment of the second arbitrator.&nbsp;&nbsp;If the first two appointed arbitrators fail to nominate a third arbitrator within this time pe<a name="_Ref255809828"></a>riod, then upon request of either Arbitration Party, the third arbitrator shall be appointed by the ICC.&nbsp;&nbsp;The third arbitrator shall serve as chairman of the Tribunal.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M478"></a><a name="_Ref302061428"></a>22.2.5<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Arbitrators&#8211;More Than Two Arbitration Parties</font>.&nbsp;&nbsp;If there are more than two&#160;(2) Arbitration Parties to the arbitration, they shall in good faith attempt to group themselves into a &#8220;<font style="font-weight:bold;font-style:italic;">Petitioning Party</font>&#8221; and a &#8220;<font style="font-weight:bold;font-style:italic;">Defending Party</font>&#8221; for purposes of selecting arbitrators.&nbsp;&nbsp;Each of the Petitioning Party and the Defending Party shall nominate one arbitrator within thirty&#160;(30) days after delivery of the Request for Arbitration.&nbsp;&nbsp;The two&#160;(2) arbitrators appointed in accordance with the above provisions shall nominate the third arbitrator within thirty&#160;(30) days of their appointment.&nbsp;&nbsp;If the first two appointed arbitrators fail to nominate a third arbitrator within this time period, then upon request of any party to the arbitration, the third arbitrator shall be appointed by the ICC.&nbsp;&nbsp;The third arbitrator shall serve as chairman of the Tribunal.&nbsp;&nbsp;If it shall not be possible to form a Petitioning Party or a Defending Party, as the case may be, or if the Petitioning Party or the Defending Party, as the case may be, fails to select an arbitrator in accordance with this <font style="text-decoration:underline;">Section 22.2.5</font>, then, in accordance with Article 10(2) of the ICC Rules, the ICC shall appoint each member of the Tribunal and shall designate one of them to act as chairman.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M479"></a><a name="_Ref302062361"></a>22.2.6<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Provisional Remedies</font>.&nbsp;&nbsp;By agreeing to arbitration, the Arbitration Parties do not intend to deprive any court of competent jurisdiction of its ability to issue any form of provisional remedy, including a preliminary injunction or attachment in aid of the arbitration, or to order any interim or conservatory measure (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Provisional Remedy</font>&#8221;).&nbsp;&nbsp;A request for such Provisional Remedy by a party to a court shall not be deemed a waiver of this agreement to arbitrate.&nbsp;&nbsp;Notwithstanding the foregoing, once the selection of the arbitrators is complete in </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">50</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">accordance with this </font><font style="text-decoration:underline;">Section 22.2</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">, the continuation, termination, amendment, or mod</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ification of any Provisional Remedy shall be determined by the arbitrators and, after an arbitration hearing is commenced, the action, suit, or proceeding commenced in such court seeking such Provisional Remedy shall be dismissed by the stipulation of all </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">parties to the relevant Dispute.&nbsp;&nbsp;In the event that any such party fails to stipulate to the dismissal of the action, the parties agree that the arbitrators may submit a stipulation dismissing the action.&nbsp;&nbsp;The arbitrators may conduct any hearings or order </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">any discovery they deem necessary to properly review the Provisional Remedy.&nbsp;&nbsp;This </font><font style="text-decoration:underline;">Section&#160;22.2.6</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> shall be specifically enforceable by each party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M480"></a>22.2.7<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Award</font>.&nbsp;&nbsp;The award rendered by the arbitrators shall be final and binding on the Arbitration Parties.&nbsp;&nbsp;Judgment on the award may be entered and the award may be enforced in any court of competent jurisdiction.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M481"></a>22.2.8<font style="margin-left:144pt;"></font><font style="text-decoration:underline;color:#000000;">Confidentiality</font><font style="color:#000000;">.&nbsp;&nbsp;Any arbitration hereunder shall be confidential, and the Arbitration Parties and their agents and the arbitrators shall not disclose to any non-Arbitration Party the subject of the arbitration, any information about the arbitration or the substance of the proceedings thereunder except as may be required by Applicable Law, for insurance purposes, or as necessary to enforce this agreement to arbitrate or any award hereunder or in connection with a request for any Provisional Remedy.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">23.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M482"></a><a name="_DV_M483"></a><a name="_Ref302551008"></a><a name="_Toc444101381"></a>MISCELLANEOUS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M484"></a><a name="_DV_M485"></a><a name="_Toc444101382"></a><font style="text-decoration:underline;">No Partnership</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The Shareholders expressly intend not to form a partnership hereby, either general or limited, under any jurisdiction&#8217;s partnership law.&nbsp;&nbsp;The Shareholders do not intend to be partners one to another, or partners as to any third party, or create any fiduciary relationship among themselves, solely by virtue of their status as Shareholders.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M486"></a><a name="_DV_M487"></a><a name="_Toc444101383"></a><a name="_Ref302064786"></a><font style="text-decoration:underline;">Discrepancies</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;If there is any discrepancy between any provision of this Agreement and any provision of the Company&#8217;s Charter Documents, the provisions of this Agreement shall prevail as between the Shareholders, and the parties shall procure that the Company&#8217;s Charter Documents are promptly amended, to the extent permitted by Applicable Law, in order to conform to this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M488"></a><a name="_Toc444101384"></a>23.3<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Notices</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M489"></a>23.3.1<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Notices</font>.&nbsp;&nbsp;Each notice, demand or other communication given or made under this Agreement shall be in writing, in English and delivered or sent to the relevant party at its address or fax number set out below (or such other address or fax number as the addressee has by five&#160;(5) days&#8217; prior written notice specified to the other parties).&nbsp;&nbsp;Any notice, demand or other communication so addressed to the relevant party shall be deemed to have been delivered, (a) if delivered in person or by messenger, when proof of delivery is obtained by the delivering party; (b) if sent by post within the same country, on the third (3rd) day following posting, and if sent by post to another country, on the fifth (5th) day following posting; and (c) if given or made by fax, upon dispatch and the receipt of a transmission report confirming dispatch.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">51</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M490"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">23.3.2</font><font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Addresses; Fax Numbers</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The initial address and facsimile for each party for the purposes of th</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">is Agreement are:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.15%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M491"></a><font style="text-decoration:underline;">for Mitsui</font>:</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:21.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M492"></a>Address: 3-1, Ohtemachi 1-Chome</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"><font style="margin-left:0pt;">Chiyoda-Ku, Tokyo, Japan 100-8631</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:21.23%;text-indent:9.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Mr. Toru Tamura, General Manager</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:30.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biochemicals Department, Specialty Chemicals Division</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:21.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M493"></a>Fax: 81-(0)3-3285-7718</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.15%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M494"></a> <font style="text-decoration:underline;">for any BioAmber Party</font>:</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:21.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M495"></a>Address: 1250 Rene-Levesque West, Suite 4310</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:21.15%;text-indent:9.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M496"></a>Montreal, Quebec, Canada, H3B 4W8</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:30.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M497"></a>Attention: Jean-Fran&#231;ois Huc, President &amp; CEO</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:21.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M498"></a>Fax: (514) 844-1414</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.15%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M499"></a> <font style="text-decoration:underline;">for the Company</font>:</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:21.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M500"></a>Address: 1250 Rene-Levesque West, Suite 4310</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:21.15%;text-indent:9.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M501"></a>Montreal, Quebec, Canada, H3B 4W8</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:21.15%;text-indent:9.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M502"></a>Attention: Fabrice Orecchioni, President</p>
<p style="margin-bottom:12pt;margin-top:6pt;margin-left:21.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M503"></a>Fax: (514) 844-1414</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M504"></a><a name="_Toc444101385"></a><font style="text-decoration:underline;">Expenses</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Except as otherwise noted herein, each Shareholder shall bear the expenses incurred by it in connection with the negotiation and execution of this Agreement and the performance of its obligations hereunder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M505"></a><a name="_DV_M506"></a><a name="_Toc444101386"></a><font style="text-decoration:underline;">Entire Agreement</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;This Agreement, the Exhibits, the Schedules and the Ancillary Agreements constitute the entire agreement among the parties relating to the subject matter hereof and thereof and supersede all prior oral and written understandings, all contemporaneous oral negotiations and discussions, and all other writings and agreements relating to the subject matter hereof and thereof (including the Term Sheet; <font style="font-style:italic;">provided</font>, that Sections I.4 (<font style="font-style:italic;">Confidentiality</font>) and I.7 (<font style="font-style:italic;">Breach</font>) of the Term Sheet shall survive in accordance with their respective terms, and nothing herein shall be deemed to release any party from any liability for any previous breach of the Term Sheet).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M507"></a><a name="_Toc444101387"></a><font style="text-decoration:underline;">Counterparts</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;This Agreement may be executed in one or more counterparts, with the same effect as if the parties had signed the same document.&nbsp;&nbsp;Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.&nbsp;&nbsp;Delivery of a signature page by facsimile or electronic means shall have the same effect as the delivery of a manually executed original thereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">52</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M508"></a><a name="_Toc444101388"></a><font style="text-decoration:underline;">Governing Law</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to its principles or rules of conflict of laws to the extent such principles or rules would require or permit the application of the laws of another jurisdiction.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M509"></a><a name="_Toc444101389"></a><font style="text-decoration:underline;">Severability</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Each and every obligation under this Agreement shall be treated as a separate obligation and shall be severally enforceable as such.&nbsp;&nbsp;If a term of this Agreement is or becomes illegal, invalid or unenforceable in any respect under any jurisdiction, that shall not affect (a) the legality, validity or enforceability in that jurisdiction of any other term of this Agreement or (b) the legality, validity or enforceability in any other jurisdictions of that or any other term of this Agreement.&nbsp;&nbsp;If a term of this Agreement is or becomes illegal, invalid or unenforceable in any respect under any jurisdiction, it shall be replaced by a mutually acceptable provision, which being valid, legal, enforceable and in compliance with applicable government policy comes closest to the intention of the parties underlying such illegal, invalid or unenforceable provision.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M510"></a><a name="_Toc444101390"></a><font style="text-decoration:underline;">Survival of Rights, Duties and Obligations</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Termination of this Agreement for any cause shall not release any party from any liability which at the time of termination has already accrued to any other party or which thereafter may accrue in respect of any act or omission prior to such termination, nor shall any such termination hereof affect in any way the survival of and right, duty or obligation of any party which is expressly stated elsewhere in this Agreement to survive termination hereof or which by its nature shall survive the termination of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M511"></a><a name="_Toc444101391"></a><font style="text-decoration:underline;">Specific Performance</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;The parties acknowledge that it may be impossible to measure in money the damages that would be suffered by a party by reason of the failure by any of the other parties to perform any of its obligations hereunder, and that irreparable damage may occur in the event that any of the provision of this Agreement is not performed in accordance with its specific terms or otherwise breached. Therefore, if a party shall institute any Proceeding to enforce the provisions hereof, a party against whom such Proceeding is brought hereby waives any claim or defense therein that the other party has an adequate remedy at law.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M512"></a><a name="_DV_M513"></a><a name="_Toc444101392"></a><a name="_Ref302553501"></a>Assignment</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M514"></a><a name="_DV_M514"></a>.&nbsp;&nbsp;No Shareholder shall assign, or suffer or permit an assignment (by operation of law or otherwise), of its rights or obligations under or interest in this Agreement without the prior written consent of the other Shareholder and the Company, except to the extent expressly permitted hereunder, and any purported assignment or other disposition by a Shareholder in violation of this Section 23.11 shall be deemed to be a breach of this Agreement.&nbsp;&nbsp;Subject to the foregoing, this Agreement shall inure to the benefit of and be binding upon the parties and their respective successors and permitted assigns.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M515"></a><a name="_Toc444101393"></a><font style="text-decoration:underline;">Amendment; Waiver</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;This Agreement cannot be amended or otherwise modified nor any performance, term, or condition waived in whole or in part, except by a writing signed by the party against whom enforcement of the amendment, modification or waiver is sought.&nbsp;&nbsp;No delay or failure on the part of any party in exercising any rights hereunder, and no partial or single exercise thereof, will constitute a waiver of such rights or of any other rights hereunder.&nbsp;&nbsp;Without limiting the foregoing, no waiver by a party of any breach by any other party of any provision </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">53</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">hereof shall be deemed to be a waiver of any subsequent breach of that or any other provision hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M516"></a><a name="_Toc444101394"></a><a name="_DV_M517"></a><font style="text-decoration:underline;"><a name="_DV_M517"></a>Limitation on Rights of Third Parties</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;This Agreement is entered into among the parties for the exclusive benefit of the parties and their successors and permitted assigns.&nbsp;&nbsp;Except as otherwise expressly provided herein, this Agreement is not intended for the benefit of any other Person.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M518"></a><a name="_Ref162086084"></a><a name="_Ref174599931"></a><a name="_Toc444101395"></a>23.14<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Confidentiality</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M519"></a><a name="_Ref162085820"></a><font style="text-decoration:underline;">Confidential Information</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M520"></a><a name="_DV_M521"></a>.&nbsp;&nbsp;In order to protect the Confidential Information of any party (a &#8220;<font style="font-weight:bold;font-style:italic;">Disclosing Party</font>&#8221;) that becomes available to any other party (a &#8220;<font style="font-weight:bold;font-style:italic;">Receiving Party</font>&#8221;), the Receiving Party agrees that (i) it shall make no use of such Confidential Information except in furtherance of the purposes of, and as contemplated by, this Agreement, and (ii) it shall not (and it shall cause its Affiliates, directors, officers, employees, agents and representatives not to) without the prior written consent of the Disclosing Party, disclose to any third party Confidential Information of such Disclosing Party, so long as such Receiving Party is a Shareholder and for a period of ten&#160;(10) years thereafter or, in the case of the Company, so long as it remains in existence; <font style="font-style:italic;">provided</font>, <font style="font-style:italic;">however</font><a name="_DV_M520"></a><a name="_DV_M521"></a>, that:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M522"></a>(a)<font style="margin-left:144pt;"></font>a Receiving Party may disclose Confidential Information to those of its Affiliates, directors, officers, employees, agents and representatives who have a need to know such Confidential Information in relation to the matters contemplated hereby and who are under obligations of confidentiality and non-use consistent with those set forth herein; <font style="font-style:italic;">provided </font>that any disclosure of Confidential Information by a party&#8217;s Affiliates, directors, officers, employees, agents and representatives that is not permitted by this <font style="text-decoration:underline;">Section 23.14</font> shall be a breach by such party of this <font style="text-decoration:underline;">Section 23.14</font><a name="_DV_M522"></a>;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M523"></a>(b)<font style="margin-left:144pt;"></font>disclosure of Confidential Information is permitted to the extent that such disclosure is required pursuant to Applicable Law; <font style="font-style:italic;">provided however</font>, that the Receiving Party shall promptly notify the Disclosing Party in writing of the existence of any such requirement and reasonably cooperate with the Disclosing Party in seeking an appropriate protective order or other reliable assurance that confidential treatment will be acc<a name="_DV_M523"></a>orded the Confidential Information;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:11.54%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M524"></a>(c)<font style="margin-left:144pt;"></font>this <font style="text-decoration:underline;">Section 23.14</font><a name="_DV_M524"></a> shall not apply to any Confidential Information which:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:30.77%;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M525"></a>i.<font style="margin-left:202pt;"></font><font style="margin-left:0pt;"><a name="_DV_M525"></a>was in the public domain or the subject of public knowledge at the time of its disclosure;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:30.77%;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M526"></a>ii.<font style="margin-left:202pt;"></font><font style="margin-left:0pt;">becomes part of the public domain or the subjec</font><a name="_DV_M526"></a>t of public knowledge through no breach by or act of default of the Receiving Party or its representatives, employees or agents;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">54</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:30.77%;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M527"></a><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">iii.</font><font style="margin-left:202pt;"></font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">is obtained by the Receiving Party from a third party other than in breach of a legal or contractual obligation of confidential</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M527"></a>ity owed by such third party to the Disclosing Party in respect thereof, the existence of which obligation was known or should have been known by the Receiving Party; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:30.77%;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">iv.<font style="margin-left:202pt;"></font>the Receiving Party establishes was independently developed by it without reference to Confidential Information.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M528"></a><a name="_Toc444101396"></a><font style="text-decoration:underline;">Advertising; Publicity</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Each party agrees not to issue any press release or otherwise make any public disclosure with respect to this Agreement, the Ancillary Agreements or the transactions contemplated hereby or thereby without the prior written approval of the other parties, unless, and only to the extent, required pursuant to Applicable Law (including the rules of any stock exchange to which such party or any Affiliate thereof may be subject), in which case, to the extent practicable, the party intending to make such disclosure shall give advance notice thereof to the other parties.&nbsp;&nbsp;Notwithstanding the foregoing, it is the parties&#8217; intent to issue a press release following the signing of this Agreement, subject to the parties agreeing to the content of such press release.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M529"></a><a name="_Ref165352830"></a><a name="_Toc444101397"></a><a name="_Ref302067717"></a><a name="_DV_M530"></a><font style="text-decoration:underline;"><a name="_DV_M530"></a>Subsequent Shareholders</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Any Person not a signatory to this Agreement who hereafter becomes a Shareholder as provided hereby shall be bound by all of the terms and provisions, and shall be entitled to all the benefits and privileges, of this Agreement.&nbsp;&nbsp;Before any Person not a signatory to this Agreement, including any Person to whom transfers of Shares may be made hereunder, may be entitled to be a Shareholder, such Person shall be required to execute and deliver to the Company an agreement, in form and substance reasonably acceptable to the Company and the Shareholders (a &#8220;<font style="font-weight:bold;font-style:italic;">Joinder Agreement</font>&#8221;) pursuant to which such Person agrees to be bound by all of the terms and conditions of this Agreement, and the failure of any such Person to do so shall preclude such Person from becoming a Shareholder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc444101398"></a><font style="text-decoration:underline;">Unanimous Shareholder Agreement</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;This Agreement shall be considered a unanimous shareholder agreement pursuant to the Canada Business Corporations Act to the extent that any provisions in this Agreement restrict, in whole or in part, the powers of the Directors to manage, or supervise the management of, the business and affairs of the Company.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M531"></a>[<font style="font-style:italic;">Remainder of Page Intentionally Left Blank; Signature Page Follows</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">55</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M532"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N WITNESS WHEREOF, the parties have signed this Amended and Restated Joint Venture Agreement as of the date first written above.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M533"></a>BIOAMBER INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M534"></a>By:<font style="text-decoration:underline;margin-left:0pt;">/s/ Jean-Fran&#231;ois Huc</font>___________&nbsp;&nbsp;<font style="text-decoration:underline;">&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M535"></a>Name: Jean-Fran&#231;ois Huc</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M536"></a>Title: President &amp; Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M537"></a>BIOAMBER INTERNATIONAL S.&#192;.R.L.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M538"></a><a name="_DV_M539"></a>By:<font style="margin-left:0pt;"><a name="_DV_M539"></a></font><font style="text-decoration:underline;">/s/ Jean-Fran&#231;ois Huc</font>___________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Jean-Francois Huc</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M540"></a>Title: Manager</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="margin-left:0pt;"></font><font style="text-decoration:underline;">/s/ Jean-Michel Hamelle</font>_________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Jean-Michel Hamelle</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Manager</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M541"></a>MITSUI &amp; CO., LTD.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M542"></a>By:<font style="text-decoration:underline;margin-left:0pt;"> /s/ Shinji Oumi</font>________________ </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M543"></a>Name:Shinji Oumi</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M544"></a>Title: G<font style="color:#000000;">eneral Manager</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;Specialty Chemicals Div.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;Performance Materials Business Unit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_DV_M545"></a>BIOAMBER sarnia INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M546"></a>By:<font style="text-decoration:underline;margin-left:0pt;">/s/ Fabrice Orecchioni</font>___________<font style="text-decoration:underline;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M547"></a>Name: Fabrice Orecchioni</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M548"></a>Title: President</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_DV_M549"></a><a name="_DV_M550"></a><a name="_DV_M552"></a><a name="_DV_M566"></a>&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">1</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">tk-598330</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Portions of the exhibit, indicated by the mark &#8220;[***],&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></p></body>
</html>
</TEXT>
</DOCUMENT>
